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ABSTRACT OF THE DISSERTATION
The Role of IFRD1 in the Recruitment and Function of Reserve Stem Cells in Regeneration and
Cancer
by
Mark Lewis
Doctor of Philosophy in Biology and Biomedical Sciences
Molecular and Cellular Biology
Washington University in St. Louis, 2019
Professor Jason C. Mills, Chair
Mature cells can reprogram into a proliferative, progenitor-like state to repair tissue following
injury and inflammation. Differentiated cells in diverse tissues can become proliferative via a
dedicated, evolutionarily conserved program we termed paligenosis. We detailed how
paligenosis occurs, in both gastric chief and pancreatic acinar cells, in a step-wise manner that
involves: 1) autodegradation of mature cell components; 2) re-expression of progenitor genes; 3)
re-entry into the cell cycle. This process is governed by mTORC1, a fundamental cellular energy
sensor and regulator of protein translation. Blocking mTORC1 permitted autophagy and
metaplastic gene induction but blocked cell cycle re-entry at S-phase. Because paligenosis is a
shared, conserved process, we reasoned that genes likely evolved specifically to regulate it. We
characterized IFRD1 as a gene that is conserved throughout eukaryotes, upregulated by
paligenosis-inducing injury, and largely dispensable for homeostatic regulation of proliferation
and differentiation. IFRD1 is critical for the injury-induced recruitment of cells into the cell
cycle in Drosophila intestine and multiple mouse tissues. Ifrd1−/− mice showed decreased
mTORC1-mediated proliferation and increased apoptosis in gastric and pancreatic paligenotic

ix

cells. mTORC1 inhibition and Ifrd1−/−;Trp53−/− experiments revealed that IFRD1 works largely
by preventing p53 from repressing the reactivation of mTORC1 during stage 3 of paligenosis.
IFRD1 is the first gene shown to regulate the conserved cellular program that recruits mature
cells for regeneration. Recruiting mature cells to proliferate following injury can reveal harbored
mutations that increase the risk for preneoplastic lesions. Thus, we analyzed the expression of
IFRD1 in colon cancer tumors and found it to be significantly associated with decreased 5-year
patient survival. Pro-paligenotic genes like IFRD1 might be harnessed to increase cellular
reprogramming to promote regeneration; alternatively, because recruiting old cells with potential
stores of somatic mutations increases risk for cancer, blocking paligenosis might prevent or treat
cancer.

x

Chapter 1: Introduction
Chapter 1.1 The Emergence of Paligenosis
Cellular plasticity in response to injury has become critical to understanding the role of
mature, differentiated cells in human disease. Numerous species and nearly all tissues
demonstrate instances of cellular plasticity. There have been relatively few Investigations of the
specific cellular and molecular mechanisms involved in this process. Limited research in this
area is due to: 1) terminology, in that there has not been an accepted, singular term used to
describe the process by which terminally differentiated cells revert their cellular state to repair
injury; and 2) a general focus of investigators on the outcomes of dedifferentiation (vs. the
process). This cellular “reprogramming” to a proliferative, regenerative state can occur in
various contexts, such as when tissue undergoes metaplasia following injury. Metaplasia is
described as a temporary change in differentiation state in a cell. Acutely, injury-induced
metaplasia enables rapid tissue repair, with full restoration of normal tissue architecture. We
primarily investigate the cellular processes involved in metaplasia in the stomach, where it is
described as SPEM (Spasmolytic Peptide Expressing Metaplasia) (Figure 1A). High doses of
tamoxifen causes SPEM and it is characterized by the loss of some differentiation markers and
the emergence of cells that express both terminal differentiation markers such as Gastric Intrinsic
Factor (GIF) or Pepsinogen-II (PGII) and a progenitor marker like Tre-foil factor 2 (TFF2)1.
Building upon the work of former Mills lab members (Greg Sibbel, Ramon Jin, and Won
Jae Huh), we understood that the first detectable morphological change in gastric chief cells is an
induction of lysosomal and autophagic machinery. We proposed that pancreatic acinar cells,
which share morphological and physiological function with gastric chief cells, would be an
1

important tissue to investigate and compare the acute injury response. Metaplasia in the pancreas
is termed ADM (Acinar-to-Ductal Metaplasia) (Figure 1B). Repeated doses of cerulein causes
ADM in pancreatic acinar cells, which is also characterized by the dedifferentiation of acinar
cells to an embryonic progenitor phenotype that expresses ductal markers. Pancreatic acinar cells
lose morphological features of a differentiated cell and express the combination of acinarspecific markers like Amylase or Carboxy-peptidase 1 (CPA1) and duct markers like cytokeratin
19 (CK19), Sry-related high-mobility group box 9 (SOX9) or mucin 1 (Muc1)2.
In addition to an upregulation of autophagic machinery, we observed that exocrine
secretory cells in both the stomach and pancreas exhibited a specific and discrete set of events
(Figure 2). The idea of a shared, conserved process of dedifferentiation was first proposed in the
work of Dr. Jason Mills and Dr. Owen Sansom3. They described, based on preliminary
observations in the lab and in the literature, that the stomach, pancreas and small intestine
activate a similar program in response to injury and inflammation. They described how secretory
cells in these tissues induced lysosomes to degrade mature cell components prior to the
expression of progenitor markers (metaplastic gene expression). The last step is that these
metaplastic cells will re-enter the cell cycle, in order to begin to repair and regenerate the
damaged tissues. The sequential nature of this process was hypothesized to have specifically
evolved to equip otherwise terminally differentiated cells with the capacity to revert to an
embryonic state, and become mitotic again. Metaplasias in the stomach and pancreas are
designed to be temporary cellular states that enable a cell to withstand certain injuries.
We proposed “paligenosis” as a dedicated term for this specific cellular process reacquiring regenerative capacity. The term paligenosis encompasses the many terms that describe
a “reprogramming” event in mature cells. Paligenosis represents a decision at the cellular level to
2

dedifferentiate and proliferate instead of being routed to programmed cell death. We predict that
failure at any stage of paligenosis would result in cellular dysfunction or apoptosis. Here, we
proposed paligenosis to define the process and demonstrate that it is a conserved program with
shared molecular and cellular regulation similar to other basic cellular processes like mitosis or
apoptosis.
Chapter 1.2 Parallels between paligenosis and apoptosis
We proposed that paligenosis is a fundamental biological process, like mitosis or
apoptosis. We believe that paligenosis is activated following injury and inflammation to enable a
decision at the cellular level to either become proliferative or activate programmed cellular
death. Apoptosis, like paligenosis, was named to describe a distinct program of cellular changes.
The term apoptosis was first used in a hallmark paper by Kerr, Wyllie, and Currie in 1972 to
describe a morphologically distinct form of cell death. While apoptosis as a termed had only
been described in 1972, components of the apoptosis concept had been explicitly described many
years previously4-6. The cellular events involved in apoptosis include blebbing, cell shrinkage,
nuclear fragmentation, chromatin condensation, chromosomal DNA fragmentation and global
mRNA decay en route to death7. The understanding of the mechanisms involved in the process
of apoptosis in mammalian cells emerged from the investigation of programmed cell death
during the development of the nematode Caenorhabditis elegans8.
Kerr and colleagues described a mechanism by which the balance between cell division
and cell loss can be managed in a newly named process termed apoptosis4. Like paligenosis,
apoptosis was described to play a basic role in tissue homeostasis with wide-ranging biological
implications4. After the initial characterization of apoptosis, little was known about the factors
3

that initiate apoptosis or of the nature of the proteins involved. At this time, apoptosis was
described as a basic cellular process that was highly conserved and involved specific cellular
mechanisms that were activated prior to the appearance of the characteristic morphological
changes. The key events in the evolution of apoptosis, include: its naming, the identification of
genes that are required for its execution and the description of subtypes that occur in a
specialized manner. In the 1980’s, the genetics of programmed cell death began to come into
view. Initially, three genes- ces-1, ces-2, and egl-1- were identified in C. elegans that, when
mutated reversed the life vs. death decision in a subset of cells9-11. Then, it was found that three
different genes- ced-3, ced-4 and ced-9- can mutate to cause the survival of all cells that
otherwise would undergo apoptosis10,12. These three genes defined the killing or execution step
of apoptosis. This time in apoptosis research represents the watershed moment when
investigators began to elucidate not only the family of genes that are important for apoptosis (ced
genes), but also the interplay between these genes and the genetics of apoptosis induction and
function13-19. Another key moment was the cloning of the ced-9 gene which revealed that the
amino acid sequence of ced-9 is similar to the protein product of the mammalian proto-oncogene
bcl-213. They found that, like ced-9, Bcl-2 is sufficient to protect worm cells from apoptosis. This
conservation of protein sequence and function was important in showing how basic cellular
processes can be evolutionarily conserved and the ability to translate findings from simple to
complex species.
Our hope is that paligenosis follows a similar trajectory. At this point, the set of cellular
processes have been named. Like ced genes, we believe that there is a set of genes that have
evolved specifically to regulate the paligenosis process. The most fundamental characteristic of a
paligenosis gene would be for it to be highly conserved. We would also hypothesize that this
4

gene, whose primary role is to regulate reserve stem cell function, would be dispensable for
normal cellular activity. We would also anticipate this gene to be called into action during the
acute injury response in numerous tissues. Within this thesis, I will describe how we have
identified the first gene specifically required for paligenosis.
Chapter 1.3 IFRD1 review
We described paligenosis as a shared and conserved process activated in response to
injury. Therefore, we initiated a bioinformatic screen to identify genes that are upregulated in the
acute injury phase. Our initial criteria for a paligenosis gene was one that may be expressed at
low or no levels normally, but then increase in response to stress. In addition, stresses that induce
conserved mechanisms like fos/jun/AP1 would also likely signal through a protein that is
important for a conserved process like paligenosis. We would, thus, expect this protein to only
affect a certain kind of stress response, but not normal development or proliferation. Our initial
screen included tissues that demonstrate metaplasia and dynamic mTORC1 activity following
injury (Stomach, Pancreas, Kidney and Liver) (Figure 3). The screen led to the identification of 8
genes that we then analyzed further to include more diverse tissues that also demonstrate the
ability to dedifferentiate in response to injury (lung and glia) (Figure 4). Atf3 and Ifrd1 were the
only two genes to be significantly upregulated in diverse tissues during the acute injury response.
My decision to pursue IFRD1 was influenced by the fact that our colleague, Dr. Deborah Rubin,
is an expert on this protein and that would enable us to quickly leverage that expertise to
investigate IFRD1 in paligenosis. ATF3 is also under active investigation in the lab.
IFRD1 (interferon related developmental regulator 1) was originally characterized as an
immediate early gene that was found to respond to mitogens such as TPA, EGF, c-Jun and FGF.
5

IFRD1 associates with the Sin3 complex and was reported to play a role as a transcriptional coregulator. Dr. Rubin described the role of IFRD1 in regulating intestinal lipid metabolism and
epithelial cell proliferation20,21. To this point, there have no reports of homeostatic pathology in
mice lacking IFRD1, other than a neurodegenerative disorder known as Spinocerebellar ataxia
(SCA)22. Neurodegenerative disorders like SCA are generally progressive diseases associated
with damage to neurons. Cells of the peripheral nervous system have an intrinsic ability to repair
or regenerate22. For example, when an axon is damaged, the distal segment activates a repair
process that begins with Wallerian degeneration. The proximal segment of the axon either
undergoes apoptosis or chromatolysis in an attempt to repair the axon. Chromatolysis results in
nuclear and nucleolar changes that enables a neuron to regenerate following injury22. This
neuronal injury response mirrors the degradation, gene expression changes and regenerative
capacity we describe in paligenosis. We hypothesize that the emergence of a defect related to
IFRD1 in neuroregeneration would be due to the fact these long-lived cells may rely on a process
like paligenosis to repair injury.
We began to generate specific criteria for a paligenosis gene and Ifrd1 became a lead
candidate for investigation. As a transcriptional co-regulator, IFRD1 could potentially regulate
large sets of genes (like a specific genetic program) via chromatin modification, compared to a
typical transcription factor which generally have more limited capacity to regulate genes.
Preliminary experiments with GFP-tagged IFRD1 in Caco-2 cells revealed that this protein can
be localized in various cell compartments (cytoplasm, nucleus and nucleolar). This suggested
that IFRD1 may then function in different parts of the cell, potentially to interpret cellular stimuli
in the cytoplasm or modify transcription in the nucleus or nucleolus. Since IFRD1 is activated
rapidly in response to injury, it may function by associating with a complex that is already
6

present in all cells that rely on paligenosis to proliferate or regenerate. Alternatively, this protein
may act as a scaffold, to bring together already present components needed for cell cycle re-entry
after injury.
We would anticipate that IFRD1 function would impact human disease, as well. A recent
paper has shown that mutations in IFRD1 are associated with gastric cancer23. Given the role of
IFRD1 in driving the stress-induced proliferative response, we would also predict that IFRD1
expression in adult cancers could also be associated with increased tumorigenesis. Functionally,
we might expect aberrant IFRD1 function to allow tumor cells to quickly switch from a
quiescent to proliferative state. Further, IFRD1 has been shown to alter lipid metabolism in
enterocytes and could, thus, regulate the metabolic status of cancer cells21,24. This metabolic
flexibility could then influence the way that cancer cells adapt to the tumor microenvironment or
it may modify sensitivity to adjuvant chemotherapy25.
Lastly, because paligenosis is shared and conserved process, we would also expect a
protein evolved to regulate it to also be conserved. We found that the major domains of IFRD1
are conserved to Schizosacchromyces Pombe. Publicly available datasets show that IFRD1
orthologs are upregulated in response to stress in both S. pombe and D. melanogaster. Thus,
Ifrd1 expression levels positively correlate with the processes of cell and tissue injury response
and regeneration in humans, mice and in lower species. For these reasons, IFRD1 became a lead
candidate as a critical regulator of paligenosis.
IFRD1 conservation and the Sin3A HDAC complex
IFRD1 has been reported to interact with the SIN3 histone deacetylase (HDAC)
complex26. SIN3 was initially identified via genetic screen by two groups in 1987-the MRC
7

Laboratory of Molecular Biology (Cambridge, England) and the University of California, San
Francisco (San Francisco, CA)-that were independently investigating the phenomena of mating
type switching in budding yeast27. SIN3 has not been shown to have intrinsic DNA-binding
abilities, but instead is thought to act as a master scaffold, providing a platform for the assembly
of numerous transcription factors and cofactors. More than two decades of research has
implicated Sin3 in numerous biological functions including: scaffolding of core histone
deacetylase (HDAC) complexes, regulation of DNA and histone methylation, nucleosome
remodeling, and N-acetylglucosamine transferase activity. SIN3 has also been found to play a
key role in the reprogramming of somatic cells by maintaining embryonic stem cell pluripotency
and promotes the generation of induced pluripotent stem cells28. In Drosophila, Rpd3 is the
ortholog for both HDAC1 and HDAC2. Inactivation of Rpd3 leads to apoptosis due to increased
JNK activity and decreased Hippo signaling. Sin3A is a key component of the Rpd3-containing
Sin3 complex and inhibition of either Rpd3 or Sin3a leads to apoptosis in Drosophila epithelial
cells29. In mammals, the SIN3-HDAC complex represses CDKN1A which enables cell cycle
progression. Loss of Sin3a in embryonic lung epithelial progenitor cells leads to upregulation of
CDKN1A and permanent cell cycle arrest in G130. In sum, loss of IFRD1 and SIN3A complex
may lead to increased CDKN1A and cell cycle arrest.
Sin3 was originally isolated as a negative regulator of transcription in budding yeast
(Saccharomyces cerevisiae). There is, however, no ortholog of IFRD1 in S. cerevisiae, but
IFRD1 does emerge in Saccharomyces pombe. Both S. pombe and S. cerevisiae share genes with
higher eukaryotes that they do not share with each other. For example, S. pombe has RNAi
machinery genes like those in vertebrates, while this is missing from S. cerevisiae31. S.
cerevisiae also has greatly simplified heterochromatin compared to S. pombe. Conversely, S.
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cerevisiae has well-developed peroxisomes, while S. pombe does not. S. cerevisiae is in the G1
phase of the cell cycle for an extended period (as a consequence, G1-S transition is tightly
controlled), while S. pombe remains in the G2 phase of the cell cycle for an extended period (as a
consequence, G2-M transition is under tight control)32. Therefore, we would predict that IFRD1
has emerged as a chromatin modifier that interacts with SIN3 to regulate transcription programs
required for G2-M transition higher eukaryotes.
IFRD1 is implicated in numerous cellular signaling pathways
IFRD1 has been implicated in large number of cellular signaling pathways. The function
of Sin3a in the cell cycle is a result of its regulation of its regulation STAT transcription
activity33. IFRD1 has also been linked to fatty acid synthesis. Long chain acyl‐CoA synthetases
(ACSL) catalyze long‐chain fatty acids (FA) conversion to acyl‐CoAs34. Inactivation of ACSL1
in mouse hearts (Acsl1H−/−) impaired FA oxidation and dramatically increased glucose uptake,
glucose oxidation, and mTOR activation. The heightened cellular stress observed in Acsl1H−/−
mice resulted in increased Atf3 and Ifrd1 expression34. In keratinocytes treated with human
papillomavirus, Ifrd1 expression is significantly downregulated following inhibition of mTOR
(rapamycin) or MAPK (MEK1- PD98059 and RAF- GW5074) pathways35. Ifrd1 deficiency led
to increased acetylation of p65 at residues K122 and K123, repressing NF-κB transcriptional
activity36. PGC-1a which is an important cellular metabolic regulator is controlled by IFRD1 in
adipocytes37. In osteoblasts, IFRD1 negatively regulates BMP-2, which is part of the TGFB/SMAD and hedgehog pathways in development38. Lastly, IFRD1 has been predicted to
downregulate B-catenin/Tcf4 transcriptional activity via its histone deacetylase activity39. All of
these pathways play a role in injury response, progenitor activity or cell cycle re-entry following
injury in our tissue models. The implication of IFRD1 in various cellular signaling pathways
9

increases its capacity to integrate the stress response in diverse cellular types and in different
contexts.
IFRD1, ribosomes and nucleolar stress
During the first stage of paligenosis, autodegradative machinery is upregulated in order to
degrade mature zymogenic cell features such as secretory granules and rough ER. This
degradation results in the release of free ribosomes. As the injury begins to resolve and
metaplastic cells prepare to enter the cell cycle, ribosomal function needs to be restored and new
ribosomes need to be generated. Ribosomes are composed of ribosomal proteins and ribosomal
RNAs, which are synthesized in the nucleolus. Ribosomal RNA synthesis is regulated RAPTOR,
an adaptor protein required for mTORC1 function40. The nucleolus is the largest structure within
the nucleus and its primary function is to assemble ribosomes. CORD, a tool to identify
coordinately expressed genes, reveals that Ddx21 is one of the highest co-regulated genes that is
co-regulated with Ifrd1. DDX21 is a key mediator of nucleolar ribosome biogenesis41. DDX21
associates with Pol I- and Pol II-transcribed genes and with diverse species of RNA. DDX21
occupies the transcribed rDNA locus, directly contacts both rRNA and snoRNAs, and promotes
rRNA transcription, processing and modification41. In the nucleoplasm, DDX21 binds 7SK RNA
and, as a component of the 7SK small nuclear ribonucleoprotein (snRNP) complex, is recruited
to the promoters of Pol II-transcribed genes encoding ribosomal proteins and snoRNAs41.

Plasma cells are lymphocytes that secrete large amounts of Immunoglobulins. To achieve
this, plasma cells expand their ER via continuous ER stress and activation of the Unfolded
Protein Response (UPR). This ER stress must be delicately managed in order to not induce
10

apoptosis. Activating transcription factor 4 (ATF4), a predicted upstream regulator of IFRD1, is
induced following LPS-induced ER stress in plasma cells. High levels of apoptosis was observed
in cells that were engineered with overactive mTOR in the presence of ER stress42. This
suggests, that protein synthesis in plasma cells is controlled by an ER stress-mediated mTOR
regulation, which is needed for optimal cell viability42.
Tunicamycin is a drug used to experimentally induce the UPR, following treatment with
Tunicamycin in erythroid progenitors, increased ribosome density is observed on Ifrd1
transcripts43. Plasma cells are also the source of multiple myelomas and inactivation of histone
methyltransferases in multiple myelomas increases Ifrd1 (GEO dataset: GSE57863). During
myogenesis, IFRD1 has been implicated in the induction histone-modifying enzymes44.
Together, these data suggest that, in cells with high secretory activity (and ribosomes), like
plasma cells, IFRD1 may help manage survival in stress conditions and function in global gene
expression patterns via chromatin modification.
The regulation of translation factor eIF2 is also important in metaplasia-inducing stress.
Phosphorylation of alpha unit of eIF2 results in the loss of its availability, but an increase in the
translation of specific transcripts like Atf3/4 and Ifrd142. Several different serine kinases target
eIF2- in the presence of stresses like amino acid starvation (GCN2), the presence of dsRNA
(PKR) or ER stress (PERK)45. The manner in which ribosomes, ER stress and the UPR influence
human diseases hinges on TP53 (p53). The literature shows that ribosomes and nucleolar activity
are key for the stabilization of p5346. There is also a close interconnection between ribosome
biogenesis and cell proliferation. Further, we know that factors that stimulate cell proliferation
also stimulate ribosome production while the ribosome biogenesis rate control cell cycle
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progression46. p53 protein plays an important balancing role between ribosome biogenesis rate
and progression through the cell cycle phases. The perturbation of ribosome biogenesis stabilizes
and activates p53, resulting in cell cycle arrest and/or the transcription of pro-apoptotic genes46.
The destabilization of ribosome biogenesis, or, potentially, through the mismatch of ribosomal
proteins and ribosomal RNAs would result in the stabilization of p53 (Figure 5). As cells proceed
through the paligenosis program, p53 could interfere, driving the cells toward quiescence or
apoptosis.
IFRD1 and p53
p53 is considered a master guardian of the genome and, like IFRD1, regulates diverse
cellular pathways. The canonical function of p53 as a tumor suppressor is to mediate cell cycle
arrest, apoptosis and the activation of DNA damage repair. p53 is known to repress target genes
via multiple mechanisms, including by recruiting the Sin3/HDAC1/2 chromatin remodeling
complex. SIN3 proteins (SIN3A and SIN3B) regulate gene expression at the chromatin level by
serving as an anchor onto which the core Sin3/HDAC complex is assembled. There is a direct
protein-protein interaction between the SIN3 complex and p5347. This suggests that IFRD1 and
P53 may interact with each other and that IFRD1 may directly or indirectly regulate the cell
cycle or apoptosis function of p53. Preliminary co-immunoprecipitation data from our lab also
suggests that there is a physical interaction between IFRD1 and p53.
The role of p53, when activated upon DNA damage sensing is to prevent progress
through cell cycle checkpoints and potentially activate apoptosis. We also know that p53 is
mutated in countless adult tumors. Given the potential relationship between IFRD1 and p53, we
would theorize that during paligenosis IFRD1 which would prevent p53 from acting prematurely
(i.e. giving a cell the “all clear” signal to progress through the cell cycle following acute, but
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manageable injury). However, a defect in IFRD1 function may instead result in reduced
proliferation (and tumorigenesis in cancers) if associated with normal p53 or a much more
devastating result in the presence of mutated P53.

Chapter 1.4 Paligenosis and GI Disease
The process of undergoing paligenosis on its own could pose a pathological risk. The
genetic changes that we observe during paligenosis (chromatin remodeling to re-express
progenitor and proliferation associated genes) may expose differentiated cells to increased risk
for mutation. A single mutation in a constitutively active stem cell is generally not thought to be
harmful because that allele would be lost through differentiation to a daughter cell or through
genetic drift. Long-lived differentiated cells, on the other hand, can harbor old mutations which
can be revealed through activation of the paligenosis program in response to injury.
Differentiated cells can acquire mutations in tumor suppressors or activating mutations, like
dominant-negative G12D KRAS, which are generally harmless, unless the cells undergo
paligenosis. Thus, differentiated cells have become good candidates for cells of origin for
cancers and, in particular, GI adenocarcinomas48. Pancreatic and gastric adenocarcinomas are
often composed of cells which share morphology with differentiated, secretory cells of each
organ. In the following sections, I will describe the potential impact of paligenosis on pancreatic
and gastric cancer research.
Modeling Paligenosis in the pancreas
Injury or inflammation can cause pancreatic acinar cells to reverse their post-mitotic,
differentiated cell state. Acinar cells acquire morphological and molecular characteristics that are
a hybrid between mature acinar cells and duct epithelial cells, which are the cells that link the
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pancreatic ducts and facilitate the transport of secreted digestive enzymes to the duodenum.
Historically, pathological analysis of ADM suggested that injury-induced duct complexes arose
from the proliferation of ducts themselves, due to the organization of the ducts into tubules.
Following the emergence of genetic lineage-tracing, it has become clear that proliferative,
tubular, duct-like cells primarily arise from mature acinar cells, which account for more than
90% of the adult pancreas49-53. Thus, these lesions have been termed Acinar-to-Ductal
Metaplasia (ADM). ADM is not the complete conversion of acinar cells to duct cells because
these metaplastic cells maintain characteristics of mature acinar cells (digestive enzymes like
amylase or carboxypeptidase 1) and those of mature duct cells (cytokeratin 19, Carbonic
Anhydrase II, and Mucins 1 and 6)49. In mice, pancreatitis and ADM can be induced via drug
administration or surgical resection54.
Prior to my joining the Mills lab, the primary focus was on the metaplastic changes in the
gastric epithelium. However, as described above Mills and Samson 2015, there was a belief that
pancreas and stomach may share a common program to dedifferentiate and repair injury. A
review of the literature led to the utilization of cerulein which is the most commonly used
method to induce ADM experimentally. Cerulein is a cholecystokinin (CCK) analog that induces
hypersecretion of acinar secretory granules. High doses of intraperitoneally injected cerulein
initially results in pancreatitis due to the damage associated with the inappropriate exocytosis of
digestive enzymes and the direct induction of pro-inflammatory cytokines55. Another
experimental model of ADM is through direct tissue injury by pancreatic duct ligation (PDL).
This method involves the suturing of a pancreatic lobe, resulting in a blockade of digestive
enzyme flow into the intestine and significant tissue injury and inflammation in the surgically
affected lobe56. In each experimental model of ADM, it is known that inflammatory cells, are
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critical for the progression to metaplasia56,57. However, the manner in which cells sense damage
and which upstream signals induce acinar cells to dedifferentiate have not been elucidated.
Pathological studies of the pancreas show that ADM is a precursor to pre-cancerous
lesions like pancreatic intraepithelial neoplasia (PanIN)58. Lineage tracing shows that mutations
in key regulatory genes can result in PanIN lesions progressing to pancreatic ductal
adenocarcinoma (PDAC)59,60. In contrast to gastric adenocarcinoma, models of pancreatic cancer
in mice show that pancreatic acinar cells progress from pancreatitis to metastasis in a similar way
to how it occurs in humans.
Paligenosis from ADM to Pancreatic Ductal Adenocarcinoma (PDAC)
Pancreatic ductal adenocarcinoma is the fourth leading cause of cancer death in the
United States and is projected to be the second by 202061. The overall 5-year survival of PDAC
is 7%61. The extremely poor prognosis of PDAC highlights the urgent need to understand and
target the molecular aberrations that drive this disease. Pancreatic intraepithelial neoplasias
(PanINs) are the most critical type of PDAC precursors. Tumorigenesis has been described as a
stepwise progression from low-grade PanINs to high-grade PanINs and then to invasive
adenocarcinoma62. Chronic pancreatitis is a significant risk factor for developing PDAC59,63,64.
The genetic events that drive pancreatic intraepithelial neoplasia (PanIN) formation and
progression to PDAC are well known and have been validated in multiple mouse models. These
involve mutations in tumor suppressor genes like CDKN2A, TP53 and SMAD4, as well as
activation of the KRAS oncogene65-67. To progress from ADM to PanIN and pancreatic cancer,
the activities of endogenous and mutant alleles of KRAS are increased58,68. During the process of
cancer initiation, crosstalk between acinar cells with KRAS mutations and inflammatory
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macrophages contributes to ADM and formation of early lesions69. However, during progression
to PDAC, the tumor microenvironment becomes immunosuppressive with a predominance of
myeloid-derived suppressor cells and regulatory T cells70. Several studies have shown that
inducing expression of constitutively active KRASG12D induces dedifferentiation and turning it
off results in redifferentiation back the acinar state71. It should be noted that active KRAS is not
sufficient to induce dedifferentiation, as injury or inflammation must also occur59,72. After
dedifferentiation, KRAS, as well as multiple steps in the canonical Ras pathway, have been
shown to be necessary and sufficient to promote and maintain the ADM state58,73,74. Upstream of
KRAS, EGF or TGFa signaling and the key downstream mediator of the KRAS signal is
Mitogen activated protein kinase 1 and 2 (MAPK1 and MAPK2; aka MEK1/2) upstream of
extracellular signal-regulated kinase 1 and 2 (ERK1/1)53,58,75. Inhibitors at each stage can block
or reverse ADM: Erlotinib and Cetuximab block EGFR interaction with its ligands, PD153035
blocks signaling from the EGFR, and the MEK inhibitors BAY 86–9766, PD325901, and
U012653,76-78.
Other important signaling pathways have been implicated in dedifferentiation and
progression to PDAC including Hedgehog, Wnt, Akt-PTEM, Notch and TGF-B. A more recently
described, non-KRAS pathway sufficient to induce ADM is the Hippo pathway. Induction of
nuclear YAP1 activity (decreased signaling through the Hippo pathway) in adult mice is
sufficient to cause ADM without affecting KRAS79. Together, these studies highlight the vast
number signaling pathways involved in pancreatic cancer development and their impact on the
initiation, maintenance and progression of oncogenic activity in pancreatic acinar cells.
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Modeling Paligenosis in the Stomach
An aspect of chief cell metaplasia that is arguably clearer than ADM is the cellular
trigger that induces reprogramming. In the stomach, death of another key functional secretory
cell, the acid-secreting parietal cell, causes loss of normal chief cell differentiation80-82. Loss or
injury of parietal cells causes chief cells to downscale their large secretory granules containing
digestive enzymes like Pepsinogen C and Carboxypeptidase B and re-express markers of mucous
neck cells (which are the precursors of chief cells in adult stomachs), like TFF2 (Spasmolytic
polypeptide), MUC6, the epitope for the lectin GS-II, and, in mice, Gastrokine 380,82-88. The
number of tools used to study the underlying mechanisms of SPEM in mice have increased over
the last decade. The administration of chemicals like Tamoxifen or DMP-777 or treatment with
the infectious bacterium Helicobacter pylori have recently been utilized to rapidly induce SPEM
in animal models of gastric dysplasia89-91. The Mills lab originally contributed to this work by
identifying that treatment with high doses of Tamoxifen can induce SPEM89. In humans, chief
cells reprogram most frequently in the setting of infection by the bacterium H. pylori, especially
in certain populations (e.g., in East Asians and in regions of Central and South Americans). In
those populations, in particular, bacteria cause widespread parietal atrophy and chief cell
metaplasia. More recently, the lab has generated a tool to directly target and kill Parietal Cells to
test the sufficiency of parietal cell loss for SPEM initiation92. Work by our lab and others has
clearly shown that chief cells reprogram to SPEM cells, however, there are no animal models of
gastric cancer that resemble human adenocarcinoma in terms of morphology, invasion and
metastasis.
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Paligenosis from SPEM to Gastric Cancer
The molecular mechanisms underlying how chief cells become metaplastic are just now
starting to be elucidated1,80,83,93. The healthy stomach is subjected to daily chemical and
microbial injuries, but manages to maintain epithelial integrity94. Studies have highlighted the
epithelial plasticity of the gastric corpus, in particular, the ability of postmitotic zymogenic chief
cells to re-enter the cell cycle and fuel the repair of injured epithelium. Plasticity of the gastric
epithelium enables the stomach to withstand significant injury but could also increase the risk for
developing gastric cancer. The glandular injury response is represented by the dedifferentiation
of zymogenic cells when acid production is compromised or lost (oxyntic atrophy). This pattern
of injury response has been termed SPEM and it is defined by the existence of cells deep in the
gastric gland that co-express proteins such as chief cell progenitor marker TFF2 (spasmolytic
peptide) and mature chief cell markers like pepsinogen (digestive enzyme). The lab of Dr. Jim
Goldenring has identified many genes whose expression is increased specifically in SPEM:
Mal2, Wfdc2 (He4), Tacc3, Mcm395,96. Most gastric cell and developmental biology research is
done under the assumption that the loss of parietal cells and mature chief cells in the corpus is
required for the development of gastric adenocarcinoma97.
Gastric Cancer, which consists predominantly of adenocarcinomas, is the fifth most
common cancer globally, and third leading cause of cancer deaths in 201298. As described earlier
in section 1.4.1 studies in pancreatic models of tumorigenesis indicate that certain oncogenic
mutations, such as constitutively active KRAS, do not have an effect in differentiated cells but
can be unmasked when they are expressed in proliferating (metaplastic) cells. In the stomach, if
mutations do not block re-differentiation as the gland recovers from injury, these mutations can
be harbored in quiescent, seemingly normal differentiated chief cells. As in pancreatic ADM, the
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initiation of SPEM (and/or parietal cell loss) is influenced by major signaling events including
Notch, sonic hedgehog, gastrin, in the epithelium, as well as, immune factors like IFN, IL-1B,
and IL-3382,99-102. Global deletion of Amphiregulin, a gene encoding an EGFR ligand, causes
spontaneous reprogramming and metaplasia of chief cells as they age 103. A
pERK→CD44→pSTAT3 signaling pathway was identified as being key to parietal cell-damageinduced proliferation during metaplasia, suggesting pERK signaling in stomach may parallel the
pancreas104.
There is a strong epidemiological link between chronic inflammation (pan-gastritis) and
metaplasia in the gastric corpus, which has increased the clinical relevance of SPEM in relation
to gastric cancer development105. There is, however, a disconnect between the location of
glandular injury and the anatomical location of gastric tumors. The majority of human gastric
adenocarcinomas seem to arise within the antrum or at the corpus–antrum transition, suggesting
that parietal or chief cell loss and metaplasia are simply surrogate markers for the overall state of
chronic inflammation in the stomach106-108. Inflammation is key to the reprogramming of gastric
chief cells, but it is still unknown whether metaplastic cells are the origin of gastric cancer109.
Most of the pathology literature related to gastric cancer focuses on gastric intestinal metaplasia
(IM), a precursor lesion to gastric adenocarcinoma. Like SPEM, gastric IM emerges after the
development of oxyntic atrophy97. Compared with SPEM, however, the cellular origin of
intestinal metaplasia is less understood, largely due to a lack of adequate animal models. It
remains to be seen whether SPEM gives rise to intestinal metaplasia or whether the two
precursor lesions can independently give rise to gastric adenocarcinoma. It has, however,
become more evident that the zymogenic chief cell plays a crucial role in the initiation of SPEM
and in repairing glandular injury110.
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In a clear parallel to ADM in the pancreas, MIST1 is also one of the first genes decreased
during reprogramming of chief cells111,112. Mist1 (bhlha15) is a basic helix-loop-helix
transcription factor that is required for the establishment and maintenance of mature secretory
cells in the stomach and pancreas. Interestingly, the upregulation of Ifrd1 that is observed
following cerulein treatment in the pancreas is blocked in cells lacking MIST1 (GEO Dataset:
GSE3644). This suggests that there may be a dependence of IFRD1 function on proper
differentiation in the mature secretory cells that undergo paligenosis.
Chapter 1.5 Summary
In summary, we describe a process by which terminally differentiated cells change their cellular
state in order to repair injury. We generated the term paligenosis to describe this process as a
shared and conserved basic cellular program and its role in the development of human diseases
in the pancreas and stomach. Since paligenosis is a shared and conserved program, we
hypothesized that there would be genes that specifically evolved to regulate this process.
Through an in silico screen of genes that were upregulated during the acute injury phase in
numerous diverse tissues, we identified Ifrd1 as such a gene. IFRD1 is highly conserved,
responsive to diverse cellular stimuli and has already been shown to be required for induced
proliferation of intestinal cells after resection. We found IFRD1 to be associated with
foundational cellular biology proteins like SIN3, p53 and mTOR and we also show that it is
associated with cellular processes like ER stress and ribosome biogenesis. Together, our
investigations show that IFRD1 may play an important role in differentiated cells that is required
to evoke a change in cellular state to respond to injury.
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Chapter 1.6 FIGURES

Figure 1.1
A

Figure 1.1A. Schematic representation of the cellular changes that occur during SPEM.
Zymogenic chief cells (RED) arise from mucous neck cells (GREEN). Following metaplasia
inducing injuries like high doses of tamoxifen (HDTAM), DMP-777, or Helicobacter pylori
infection leads to the cellular changes associated with SPEM. The SPEM cell (YELLOW) is a
hybrid cellular state between the mucous neck cell and the terminally differentiated zymogenic
chief cell.
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Figure 1.1
B

Figure 1B. Schematic representation of the cellular changes that occur during ADM. Pancreatic
acinar cells (RED) arise from pancreatic duct cells (GREEN). Following metaplasia inducing
injuries like pancreatic duct ligation or repeated doses of CCK-analog leads to the cellular
changes associated with ADM. The ADM cell (YELLOW) is a hybrid cellular state between the
pancreatic duct cell and the terminally differentiated pancreatic acinar cell.
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Figure 1.2

Figure 1.2. Schematic representation of the cellular and molecular changes that occur during
Paligenosis. Paligenosis describes the process by which terminally differentiated cells can alter
their cellular state to repair injury. We originally detail this process in the stomach in pancreas to
include 3 steps: 1) upregulation of autophagic machinery, 2) expression of a metaplastic gene
program and 3) re-entry into the cell cycle. This process is governed by mTORC1 which is a
fundamental cellular energy sensor that controls translation.
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Figure 1.3

Figure 1.3. Schematic representation of the in silico screen used to identify IFRD1 as a gene that
is important in the paligenosis process. I compared RNA expression in gene lists from gastric
chief and pancreatic acinar cells at homeostasis to SPEM and ADM cells, respectively. Ifrd1 was
one of the few genes upregulated in both the pancreas and stomach during the acute injury
response en route to metaplasia.
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Figure 1.4

Figure 4. Representation of the in silico screen to identify genes that are important for
paligenosis in multiple organs. a: Eight genes are upregulated in the pancreas, stomach, liver and
kidney during the acute injury phase. These 4 tissues represent those that we have evidence for a
paligenotic injury response. b: Expanded list of tissues that we hypothesize would also employ
paligenosis to repair injury, due to the characteristics of dedifferentiation in both lung and glial
cells. Atf3 and Ifrd1 are the only two genes to exhibit consistent upregulation during the acute
injury phase in all 6 injury models.
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Figure 1.5

Figure 5. Schematic representation of the relationship between ribosomal/nucleolar stress and
P53 expression and stabilization. Left: At homeostasis, p53 is bound by MDM2 and targeted for
degradation through ubiquitination. Normal ribosomogenesis occurs. Right: During stress, there
can be an imbalance between ribosomal RNAs and ribosomal proteins which can lead to an
interaction between ribosomal proteins and MDM2. This results in the stabilization of p53 and
transcription of p53 genes associated with cell cycle arrest and apoptosis.
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Chapter 2.1 INTRODUCTION

In 1900, George Adami wrote about the relationship between mitotic and differentiated
cells, stating that he expected mitotic cells would generally devote energy toward replication and
differentiated cells toward performing physiological functions (Adami, 1900). He also observed
that upon injury, differentiated cells had the capacity to revert to a more primitive state,
becoming mitotic again to promote tissue repair. Adami's observations on such cellular plasticity
have largely been forgotten, as the focus in the 20th century was nearly exclusively on the
unidirectional differentiation of stem cells into functional, “post‐mitotic” cells.

However, over the past decade or two, numerous examples have emerged to support
plasticity in differentiated cells. First, it became clear that normal, somatic cells could be
reprogrammed to pluripotency (Takahashi & Yamanaka, 2006). Furthermore, in tissues, injury
can induce a repair process that recruits largely post‐mitotic, differentiated cells back into the
cell cycle in most, if not all, organs and species, for example, glia (Boerboom et al, 2017;
Mindos et al, 2017); lung (Logan & Desai, 2015); heart in mammals (Wang et al, 2017) and fish
(Karra et al, 2015); in multiple gastrointestinal tract organs (Mills & Sansom, 2015). Each such
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example to date has been studied essentially in isolation within the context of a particular type of
injury and a single organ; however, because the process is so widespread, we have postulated
that it may be governed by a shared, evolutionarily conserved molecular and cellular program
that is independent of tissue and species (Mills & Sansom, 2015).

It has long been known that the response of both the corpus of the stomach and the
digestive‐enzyme‐secreting (exocrine) pancreas to certain types of injury involves phenotypical
changes in cell differentiation and tissue architecture, known as metaplasia. In the acute setting,
the metaplastic response appears to be a tissue repair mechanism and can be temporary, with full
restoration of normal tissue architecture (Nomura et al, 2005; Huh et al, 2012). Chronically,
however, ongoing damage and long‐term metaplasia are associated with and may fuel the
majority of gastric and pancreatic adenocarcinomas (Mills & Sansom, 2015; Giroux & Rustgi,
2017; Storz, 2017). In both organs, the cells of origin for the metaplastic, proliferating epithelial
cells are thought to be differentiated secretory cells (zymogenic chief cells in the stomach and
acinar cells in the pancreas) that reprogram to re‐enter the cell cycle (Mills & Sansom, 2015;
Murtaugh & Keefe, 2015; Mills & Goldenring, 2017; Radyk & Mills, 2017).

Here, we report that differentiated cells in both pancreas and stomach exhibit high levels
of mTORC1 activity during homeostasis. Proliferation‐inducing injury caused rapid mTORC1
loss and a dramatic induction of autodegradative machinery (lysosomes and autophagy). As the
functional and structural components were recycled, cells changed gene expression patterns (e.g.,
inducing the metaplastic marker Sox9); thereafter, they reactivated mTORC1 and re‐entered the
cell cycle. Such changes in mTORC1 activity were corroborated in tissues from human patients.
Also, established models of injury to differentiated cells in mouse liver (Espeillac et al, 2011)
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and kidney (Chang‐Panesso & Humphreys, 2017) correlate mTORC1 activity with the recruited
proliferating cells. Blocking mTORC1 with rapamycin in murine pancreas and stomach impaired
only cell cycle re‐entry but not earlier cellular changes. Differentiated cells in autophagy‐
defective Gnptab−/− mice were blocked from both SOX9 expression and cell cycle re‐entry
phases, consistent with the upstream autodegradative phase being necessary for downstream
mTORC1‐mediated S‐phase entry.

Our results in the context of numerous previous reports on cellular reprogramming lead
us now to propose that recruiting differentiated cells into a regenerative phenotype occurs via
stepwise metabolic and molecular phases that constitute a conserved, fundamental, cellular
program, akin to mitosis or apoptosis. This cellular program occurs during cell fate changes of
various types (e.g., reversion, dedifferentiation, transdifferentiation, reprogramming). The lack of
a standard term for the actual cellular process itself impedes finding shared features that
transcend cell types, tissues, and model systems. We propose a new, unifying term: “paligenosis”
from the Greek: pali/n/m(meaning backward or recurrence) + genea (born of, producing) + osis
(an action or process).

Chapter 2.2 RESULTS

Diverse organs show similar changes in metabolic activity during acute injury
To induce injury in the stomach, we employed a high‐dose tamoxifen (“HD‐Tam”) injury
model that has been used by us and others (Huh et al, 2012; Burkitt et al, 2017; Lee et al, 2017;
Leushacke et al, 2017). HD‐Tam causes loss of nearly all acid‐secreting parietal cells in the body
of the stomach (Figs EV1 and EV3) and induces mature, differentiated digestive‐enzyme‐
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secreting chief cells at the base of the unit to give rise to a proliferating cell population (Radyk et
al, 2018). These former chief cells maintain low‐level expression of some mature chief cell
markers and induce expression of wound repair‐associated genes like mucins and TFF2 (aka
spasmolytic polypeptide). The pattern of parietal cell loss and abundant, proliferative cells co‐
expressing TFF2 and chief cell markers has been called spasmolytic polypeptide‐expressing
metaplasia (SPEM) or pseudopyloric metaplasia (Schmidt et al, 1999). Maximal parietal cell loss
and proliferation stemming from chief cells occurs at 3 days after the first dose of tamoxifen
(Schematized in Fig 1A). By 7 days, parietal cells have returned, and the entire stomach
regenerates to pre‐treatment cell censuses within 14–21 days (Huh et al, 2012). HD‐Tam is a
rapid, synchronous method to model, in a manner that lends itself to molecular analyses, the
mechanisms of stomach repair that also occurs in human stomachs infected with the bacterium
Helicobacter pylori.
To induce injury in pancreas, we used a well‐described rapid method involving daily
injection of the secretagogue cerulein. Cerulein injections cause large‐scale damage to the
digestive‐enzyme‐secreting acinar cells of the exocrine pancreas (Adler et al, 1985; Niederau et
al, 1985; Saluja et al, 1985). To repair the damage, acinar cells re‐enter the cell cycle, forming
duct‐like structures called ADM (acinar‐to‐ductal metaplasia; schematic in Fig 1A). In our
protocol, ADM peaks 5 days after commencement of cerulein. Thereafter, there is continued
damage if cerulein administration is maintained, but the pancreas gradually adapts to the injury
over 2 weeks. Similar to HD‐Tam injury in the stomach, cerulein injury models a metaplastic
process that can also be a precursor for pancreatic ductal adenocarcinoma.
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To determine whether the reversion from the differentiated to the replicative state
involves conserved shifts in cellular energy use, we examined metabolic activity in both tissues
using phosphorylated ribosomal S6 protein (pS6). The principal mediator of S6 phosphorylation
is the S6 kinase enzyme via the cellular metabolism hub mTOR complex 1 (mTORC1). To
confirm that S6 phosphorylation depends on mTORC1 activity, we treated mice with rapamycin,
a specific inhibitor of the mTORC1‐mediated S6 kinase activity. We used an antibody against
residues 240/244 of S6, because those sites are phosphorylated principally by pS6 kinase 1,
whereas the 235/236 phosphorylation sites can have input from other signaling pathways. For
example, 235/236 can be phosphorylated by p90 ribosomal S6 kinases that can be activated via
ERK signaling (Roux et al, 2007). Figure EV1shows that rapamycin, which is a specific inhibitor
of mTORC1‐mediated S6 Kinase activity, abolished pS6 240/44 staining, which was normally
abundant in gastric pit cells nearer the stomach lumen and in gastric chief cells. Rapamycin also
blocked S6 phosphorylation efficiently during the HD‐Tam protocol (Fig EV1). Antibodies
against 235/236 also showed strong phosphorylation at peak metaplasia as well as a similar
abrogation of staining in the presence of rapamycin (Fig EV1). As anti‐240/244 antibodies have
stronger signal in our experiments and are more specific for mTORC1‐mediated
phosphorylation, we will use anti‐240/244 pS6 as a surrogate for mTORC1 activity for the
remainder of the manuscript unless otherwise mentioned.
HD‐Tam or cerulein caused dramatic changes in pS6 expression. In stomach, pS6 was
largely lost by 12 h. By 3 days, when SPEM is maximal in this system, the entire gastric unit
expressed abundant pS6 (Fig 1B). Molecular and cellular changes in the stomach following HD‐
Tam are sufficiently synchronous across the whole stomach that quantitative, molecular
approaches can be used (Huh et al, 2012). Quantitatively, phosphorylation status of both pS6
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240/244 and 235/236 in the corpus of the stomach was decreased by nearly half within the first 4
h and returned to at or above baseline by 48 h (Fig 1C). In pancreas, despite a slower and less
synchronous time course, the same pattern of mTORC1 activity could be observed by
immunofluorescence. pS6 was abundant in acinar cells at baseline, was nearly undetectable by
24 h, and recovered in many cells by day 5, when ADM is maximal (Fig 1D).
Thus, both tissues, when recruiting proliferative cells for repair, undergo a well‐defined
pattern of changes in mTORC1 activity. During homeostasis, the organs are replete with
differentiated secretory cells that are not dividing but are energetically active in synthesizing
protein using their elaborate secretory apparatus (Mills & Taghert, 2012; Lo et al, 2017). When
replicating cells must be recruited from those differentiated cells, the cells shut off mTORC1
temporarily, then re‐induce it at the time of maximal regenerative proliferation.

To further assess whether the upregulation of pS6 is a common feature during the
recruitment of differentiated cells to regenerate damaged tissue, we examined liver (two‐thirds
partial hepatectomy) and kidney (tunicamycin‐induced acute injury) for changes in S6
phosphorylation. Both injury models have previously been shown to involve recruitment of
differentiated cells back into the cell cycle (Newberry et al, 2008). In kidney, as expected,
tubules in the cortex and outer medulla are damaged as evinced by vacuolation (Fig EV2). Non‐
damaged tubules show increased BrdU as cells re‐enter the cell cycle (Fig EV2). The
proliferative tubules show marked increase in pS6. Similarly, the well‐known recruitment of
hepatocytes into the cell cycle 48 h following partial hepatectomy is also accompanied by
increased S6 phosphorylation (Fig EV2).
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Rapamycin had equivalent effects on the pancreas. Metaplastic induction of SOX9 was
not affected (Fig EV4); however, cell proliferation was even more substantially blocked than in
the stomach (Fig 2D and E). This may be because the pancreas is entirely dependent on
reprogramming acinar cells as a source for proliferation, whereas the stomach also has a
constitutive stem cell that continues to proliferate even in the presence of rapamycin (Fig 1A).
Continued HD‐Tam injections kill mice, so we cannot study adaptation of stomachs; however,
we have maintained cerulein injections for up to 2 weeks by which point wild‐type pancreas
usually adapts to the injury. Thus, we used the pancreas to determine whether mTORC1‐
dependent proliferation was required for pancreatic repair. Figure EV3 shows that 2‐week
cerulein with mTORC1 blocked led to tissue loss relative to cerulein treatment alone.

Changes in mTORC1 also characterize human metaplasia

To determine whether mTORC1 activity is modulated in human disease states, we first
examined a database of stomach tissues from human patients exhibiting metaplastic response to
H. pylori infection, previously compiled at Washington University (Lennerz et al, 2010; Radyk
et al, 2018). A representative region from this dataset is shown in Fig 3A. As in mice,
morphologically normal chief cells showed high pS6. In regions of SPEM, pS6 abundance
varied. In lesions that had histological features of cells undergoing acute conversion to SPEM
(what we have previously termed “hybrid SPEM” (Lennerz et al, 2010; Radyk et al, 2018) based
on examination of a large dataset of SPEM lesions), pS6 levels were high (Fig 3A). In regions
where basal cells showed more uniform metaplasia (“established SPEM”), pS6 levels were
lower. In humans, SPEM is thought to be either transient and rapidly resolve (as in the mouse
HD‐Tam model) or chronic and persist for decades, involving large patches of the stomach
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(Peterson, 2002). In the chronic case, SPEM is equivalent to the lesion pathologists call chronic
atrophic gastritis (Rugge et al, 2008). In addition, SPEM is thought to progress to (or predate)
another, proliferative, pre‐cancerous lesion, intestinal metaplasia (Yoshizawa et al, 2007; Correa
& Piazuelo, 2012; Spechler et al, 2017) and to increase risk for progression to a cytologically
atypical lesion, dysplasia, as well as to cancer itself.

To further clarify the link between mTORC1 activity and metaplastic changes in humans,
we analyzed pS6 levels in gastric tissue microarrays (Appendix Table S1) comprising tissue
cores representing the following histological phenotypes: normal mucosa, SPEM, IM, dysplasia,
and gastric adenocarcinoma. pS6 showed consistent, mid‐level expression in nearly all normal
mucosal samples, in agreement with our smaller sample showing expression of pS6 in normal
chief cells and with our mouse data (Fig 3B). Both cancer and dysplastic lesions showed higher
average pS6 expression, though there was also more variability in that over a third of such
lesions showed much stronger expression than normal tissue, while about a third showed lower
expression (Fig 3B). On average, intestinal metaplasia pS6 levels were close to those of normal
mucosa (Figs 3B and EV5). SPEM lesions showed a clear biphasic pattern with the majority like
the “established SPEM” with low‐to‐no detectable pS6 (cf. Figs 3A and EV5) but with some
SPEM lesions having much stronger pS6 (Figs 3 and EV5).

SPEM lesions with lower pS6 activity tended to express abundant mucin as well as
epitope for the SPEM‐identifying lectin GSII (Fig 3A); nuclei tended to be flat and eccentric (Fig
EV5). pS6‐expressing SPEM cells were more cuboidal columnar, resembling the SPEM cells in
the acute, proliferative mouse SPEM that resolves in a few days after HD‐Tam. We hypothesized
that SPEM with increased pS6 represented metaplastic cells that are actively proliferating (like
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D3 HD‐Tam in mice) to repair an injury, whereas the decreased pS6 lesions of established SPEM
may be mitotically quiescent. Hence, we divided the SPEM lesions into mitotically active
(“proliferative SPEM”) and inactive (“quiescent SPEM”) based on Ki‐67 staining of the same
tissue core on another microtome section (Fig EV5) and then correlated those phenotypes to the
previously scored pS6 expression for that lesion. Proliferative SPEM was far more likely to be
associated with pS6 expression, whereas quiescent SPEM was largely negative for pS6 (Fig 3C,
P < 0.001 by χ2). Thus, pS6 is low‐moderate in normal, physiologically active mucosa and high
in most lesions that have increased proliferation (proliferative SPEM, IM, dysplasia, cancer). We
conclude that metabolic activity correlates with differentiation state and recruitment into the cell
cycle in humans as well as mice.
Loss of mTORC1 inhibits cell cycle progression at S‐phase

Because gastric chief cells respond to injury more synchronously than pancreatic acinar
cells, we are able to perform molecular analyses based on changes of gene expression. We used
this approach to determine specifically where the block in cell cycle re‐entry occurs when
mTORC1 activity is inhibited. We analyzed Affymetrix GeneChips of whole gastric corpora
±HD‐Tam (3D) ±rapamycin by Gene Set Enrichment Analysis (GSEA) with a combination of
both a publicly available and custom gene sets. In a control experiment to validate our approach,
we dissociated gastric epithelial cells from Atp4b‐Cre; ROSA26mTmGmouse stomachs and used
flow cytometry to isolate parietal cells (GFP+) from other epithelial cells (Tomato+). Expression
of isolated, amplified RNA applied to GeneChips was analyzed by Partek Genomics Suite, and
the 94 genes whose expression was enriched ≥ eightfold in parietal cells vs. other epithelial cells
was computed. As expected, GSEA showed that these PC‐enriched genes were highly
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preferentially expressed in control stomachs vs. HD‐Tam stomachs; the addition of rapamycin
did not affect this pattern (Appendix Fig S1). Thus, global gene expression profiling with GSEA
can detect the loss of parietal cells that epitomizes HD‐Tam‐induced metaplasia and also shows
that parietal cell loss is independent of mTORC1, consistent with the histological data. In another
control experiment, we performed GSEA of a published gene set of mature chief cell enriched
genes (Capoccia et al, 2013) and contrasted HD‐Tam vs. HD‐Tam + rapamycin. There was no
substantial effect of rapamycin, suggesting that the change in chief cell gene expression induced
by injury is also not substantially affected by loss of mTORC1 (Appendix Fig S1).

On the other hand, although many transcripts from a previously published gene set of
SPEM‐associated genes (Nozaki et al, 2008) did not show particular changes when rapamycin
was administered in HD‐Tam, there was a cluster of genes enriched only when mTORC1 levels
were normal (Appendix Fig S1). Injury that causes metaplasia induces both wound‐healing‐
associated genes (e.g., Clu, Sox9, CD44v) and proliferation‐associated genes. Given that
rapamycin blocks proliferation specifically in our histological analysis, we next examined the
effects of rapamycin on the cell cycle using GSEA. Figure 4A shows that, indeed, rapamycin
induces a marked de‐enrichment of cell cycle gene expression in HD‐Tam. The block appears
specifically at the S‐phase and beyond, as gene sets for G1‐S, S, G2, and G2‐M showed that G1‐
S genes were relatively similarly distributed regardless of mTORC1 activity, whereas genes
expressed during the later stages in the cell cycle were skewed toward the HD‐Tam alone
condition (Fig 4B–E). We used a slightly different approach to further investigate the interaction
of mTORC1 with cell cycle stage by first determining the top 20 genes skewed most toward the
HD‐Tam (vs. vehicle‐treated controls) in each cell cycle stage gene set. We then determined the
average increased expression of those genes in both HD‐Tam and HD‐Tam + rapamycin vs.
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vehicle controls. Figure 4F shows that rapamycin decreased expression of the 20 top G1/S‐phase
HD‐Tam‐enriched genes by only 16 ± 3%, whereas gene expression at other cell cycle stages
was inhibited substantially more. Expression of G2/M‐phase genes was decreased by 49 ± 3%
with rapamycin treatment (P < 0.001, HD‐Tam vs. HD‐Tam + rapamycin in G2‐M genes; P <
0.05 for G2‐M vs. G1‐S).

To independently validate the GeneChip findings, we performed qRT–PCR that showed
that the expected decreases in a parietal cell (Atp4b) transcript and increase in a non‐cell‐cycle
SPEM transcript (Clu) were not affected by rapamycin (Fig 4G). Also matching the GeneChip
results, the G1 transcript, Ccnd1, was increased similarly regardless of mTORC1 status. As
expected, a G2/M‐phase transcript cohort was uniformly increased in HD‐Tam but not in HD‐
Tam + rapamycin (Fig 4H). Thus, molecular analysis indicates that inhibition of mTORC1
activity does not substantially affect chief cell G1‐phase entry from the quiescent, G0 state but
slows S, G2, and M‐phase progression. BrdU uptake and incorporation into DNA occurs during
S‐phase; thus, the block in BrdU seen histologically corroborates the molecular data suggesting
that mTORC1 is required for G1 to S transition.

Autodegradative machinery is massively upregulated early following injury

We so far have observed that mTORC1 activity is rapidly extinguished within hours of
inducing injury. Later, as cells re‐enter the cell cycle, mTORC1 is rekindled. Blocking re‐
emergence of mTORC1 activity inhibits induced proliferation in both stomach and pancreas. In
pancreas, where repair is entirely dependent on reprogramming, loss of mTORC1 activity blocks
tissue regeneration. We hypothesized that the scaling down of mature cell architecture to “retool”
a cell for more efficient proliferation would likely involve activation of lysosomes and
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autophagic machinery. The autodegradation of cellular structure could then liberate key
macromolecules (nucleotides, amino acids, lipids) that would both stimulate mTORC1
reactivation and provide building blocks for replication. Figure 5 shows that there is a massive
increase of lysosomes (by luminal marker Cathepsin D, Fig 5A) and autophagosomal puncta (by
LC3‐GFP, Fig 5C) early following injury in gastric chief cells. Figure 5B quantifies a large spike
in lysosomes, as a percentage of their PGC+ (pepsinogen C; chief cell marker) cell area, by 12–
24 h of HD‐Tam that begins to resolve by later stages, when many cells have re‐entered the cell
cycle. Increased lysosomes, autophagosomes, and autolysosomes can also be seen at the
ultrastructure level (Fig 5D and E) on transmission electron microscopy (tEM). tEM analysis
shows that rER, mitochondria, and secretory granules are all targeted for recycling during these
early stages. The pancreas also shows an equivalent time course of changes in autodegradative
machinery, with a spike in lysosome and autophagic puncta 8–24 h following cerulein, followed
by decreasing, but still elevated levels, at D3 and near baseline levels at the time of maximal
proliferation and pS6 activity (D5: Fig 5F, Appendix Fig S2).

Autodegradative machinery is required for normal progression to later stages

We next sought to address whether autodegradative machinery activation is both
upstream of and required for metaplasia formation and proliferation. To do this, we used mice
defective in lysosomal hydrolase trafficking that have been shown previously to have defects in
autodegradative function specifically in exocrine secretory cells like chief and acinar cells
(Boonen et al, 2011). Gnptab−/− mice are deficient in an enzyme required for the addition of
mannose‐6‐phosphate to lysosomal enzymes to ensure their proper trafficking. We treated
Gnptab−/− and littermate controls (Gnptab−/+ and Gnptab+/+) with HD‐Tam or cerulein. HD‐Tam
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treatment in Gnptab−/− mice caused the expected loss of parietal cells; however, chief cell
reprogramming was dramatically compromised (Fig EV6). Most units did not show loss of large
chief cells with eccentric nuclei at all (red arrowhead, Fig EV6), suggesting reprogramming did
not occur, whereas some gastric units showed complete loss of the base zone where chief cells
normally reside (green arrowhead, Fig EV6), indicating chief cells were aberrantly lost instead of
reprogrammed. Rarer gastric units seemed to complete the reprogramming (yellow arrowhead,
Fig EV6). In pancreas, we detected almost no ADM in Gnptab−/− mice (Fig EV6) by D5. Rather,
cells remained in an aberrant acinar morphology with considerable loss of eosinophilic
cytoplasm but no decrease in size. By 2 weeks, whereas wild‐type controls had largely adapted
to the cerulein injury, in Gnptab−/− mice, the exocrine pancreas comprised only scattered ducts
and SOX9− acinar cells, still organized in typical lobules. Cytologically, these remnant cells
were characterized by generous pale cytoplasms ranging from foamy to hyaline and lacking
nearly all distinguishing features.
We next examined the molecular phenotype of the block in Gnptab−/− mice. In control
stomachs in response to injury, reprogramming cells in the base showed the expected abundant
increase in metaplastic genes like Sox9 (Fig 6A) and the epitope for GSII (Fig 6C). Proliferation
in the base of the unit, where chief cells were reprogramming, was nearly equivalent to the rate
of proliferation in the normal stem cell zone in the neck (Fig 6B and D). The bases of gastric
units in Gnptab−/− mice were markedly compromised in both metaplastic changes and
proliferation (Fig 6A–D). In Gnptab−/− mice, chief cells in the base remained both BrdU‐ and
SOX9‐negative (Fig 6E and F). They also failed to reactivate mTORC1, as pS6 in these mice
was largely not detectable in the base (Fig EV7).
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In the pancreas, there was a similar defect in both BrdU (Fig 6G and I) and Sox9 (Fig
6H). The remnant acinar cells that remained in Gnptab−/− mice following 2 weeks of cerulein
treatment expressed E‐cadherin and low levels of amylase but were not positive for other mature
acinar nuclear markers like GATA4 or metaplasia markers like CK8/18 (Appendix Fig S3).

Finally, to determine whether the dropout of gastric bases was due to increased cell death
in the absence of lysosomal hydrolase activity, we examined tissue for cleaved caspase 3. In
wild‐type mice (either with or without rapamycin), we did not detect substantial apoptotic death
of the chief cells, consistent with our previous observations that death in HD‐Tam is essentially
confined to parietal cells (Huh et al, 2012; Radyk et al, 2018; Fig EV1). In Gnptab−/− mice,
however, we frequently observed multiple cells in some bases of gastric units that were
undergoing apoptosis (Appendix Fig S4). Thus, in stomach, aberrant autodegradative function
leads either to stalling of the chief cell reprogramming process or cell death. In pancreas, we
observed a pattern of scattered apoptosis of acinar cells in wild‐type mice ±rapamycin following
cerulein treatment. Loss of GNPTAB did not seem to affect this basal rate of death, which is
consistent with the survival of many acinar cell remnants out to 2 weeks, as discussed above.

Chapter 2.3 DISCUSSION

There has been a recent burgeoning of examples of cellular plasticity in tissue in response
to injury, not to mention a growing, already large literature on in vitro systems for
reprogramming cells back to progenitors. The instances of such plasticity span numerous species
and nearly all tissues. Despite the breadth of examples of cellular reprogramming, studies
focusing on the specific molecular mechanisms responsible for the process are still relatively
scant. This is particularly true in studies of cells in tissue, likely because investigators have
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focused more on the outcome of cellular reprogramming—regeneration or tumorigenesis—than
on the stepwise mechanisms differentiated cells use to contribute to those outcomes. Here, we
have speculated that there could be a shared cellular program that governs the many diverse
examples of differentiated cells changing their fate to facilitate repair. There have been many
terms that either focus on the outcome of the program or are overly broad: “dedifferentiation”,
“transdifferentiation”, “reversion”, “reprogramming”. We now propose “paligenosis” as a
specific term describing the cellular process differentiated cells use to re‐acquire regenerative
capacity. We highlight that paligenosis may be a conserved cellular process with shared
molecular and cellular regulation akin to other basic cellular processes like mitosis and
apoptosis.

To support our assertion that there may be a shared program for recruiting differentiated
cells, we have analyzed the cellular and molecular changes that occur during injury‐induced
reprogramming in two distinct organs. Upon injury, both the stomach and pancreas have the
capacity to repair tissue damage through the recruitment of fully differentiated cells into a less
differentiated, proliferative state to replenish cell numbers. This pattern of change in cell
phenotype is known to pathologists as metaplasia. We find that the cellular and molecular
changes that characterize cells undergoing such metaplastic injury response in either stomach or
pancreas are remarkably similar. Specifically, we found that acutely following injury,
autodegradative pathways increase alongside a decrease in mTORC1 activity (Fig 7). As the
injury progresses, we observed the induction of genes that are known to occur during metaplasia
followed by the rise of mTORC1 activity and increased proliferation (Fig 7). A similar pattern of
changes in mTORC1 activity relative to metaplasia and the differentiated vs. proliferative
phenotype was observed in human patients. We found that mTORC1 activity was specifically
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required for progression through S‐phase. Previous literature has also shown that mTORC1
activity is critical for S‐phase progression of cancer cells following DNA damage, as mTORC1
is needed to generate pyrimidines in a nutrient‐poor environment (Robitaille et al, 2013; Silvera
et al, 2017; Zhou et al, 2017). mTORC1 activation is also needed for yeast to pass through G1
into S‐phase as they emerge from quiescence (Dhawan & Laxman, 2015; Moreno‐Torres et al,
2015). Using an animal model of lysosomal dysfunction, we uncovered that normal lysosomal
function after injury is required for cell phenotype and gene expression changes associated with
metaplasia. In pancreas, where constitutive stem cells are not available for regeneration, loss of
either autodegradative function or mTORC1 activity compromised eventual organ repair.

Recent advances in the understanding of how mTORC1 is controlled have described a
role for the lysosome as an activator of the pathway through the release of nutrients like key
amino acids (Zoncu et al, 2011). Thus, our current working model is that due to injury‐induced
stress, autodegradative pathways are upregulated, and flux increases. The activation of
autodegradative pathways appears to act in parallel with loss of the mature gene regulatory
network, as forcing expression of key mature‐cell‐promoting transcription factors like MIST1
(BHLHA15) impairs the injury/repair process (Direnzo et al, 2012; Lo et al, 2017). MIST1
controls a cassette of genes that help direct a cell's energy toward secretion and away from
lysosomal activation and autophagy (Mills & Taghert, 2012). We reason, as did Adami over a
century ago, that to convert from the differentiated state (structurally complex, energetically
active) to the replicative state (structurally simple, energetically active), cellular energy use must
be repurposed as an autodegradative program is activated to convert differentiated cell structure
into building blocks for replication. The release of nutrients through the lysosome is sensed in
cells during the autodegradative phase, resulting in reactivation of mTORC1, which, once the
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cell has reached sufficient energy levels, subsequently facilitates cell cycle progression and
growth to replace cells lost during the injury.

Pancreatic adenocarcinoma and—to a lesser extent—gastric adenocarcinoma are
commonly driven by oncogenic mutations in Kras. In mouse models in both the pancreas
(Hingorani et al, 2005) and stomach (Choi et al, 2016), KrasG12D mutations, in concert with
tissue inflammation, promote changes in gene expression and cell phenotypes resembling injury‐
induced metaplasia. In the pancreas, genetically disabling autophagy in the context of K‐Ras
mutations prevents K‐Ras from driving high‐grade lesions (Rosenfeldt et al, 2013). Furthermore,
cells unable to phosphorylate S6 in the context of activating K‐Ras mutations also exhibit less
pancreatic cancer progression (Khalaileh et al, 2013). A similar critical role for mTORC1
downstream of another key driver oncogene pathway, Wnt activation mediated by APC
mutation, has been described in intestinal carcinogenesis (Morran et al, 2014). Thus,
tumorigenesis in diverse tissues may also involve modulating lysosomal activity and mTORC1,
similar to what we observe in our injury models here. Other pathways downstream of K‐Ras,
such as PI3K/Rac1 signaling (Heid et al, 2011; Wu et al, 2014), also play similar roles in injury‐
induced metaplasia.

If there truly is a shared cellular program, paligenosis, underlying the process of
recruiting mature cells to become regenerative cells, we would expect the general features we
have described here in stomach and pancreas to be recapitulated in many other tissues and
species. Obviously, it will be important to conduct new studies in other systems to begin to
support that assertion; however, we can at this point re‐examine the extant literature to determine
whether roles for lysosomes/autophagy and/or mTORC1 in the process of cellular
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reprogramming to a regenerative state have previously been described. One such previous study,
using a different injury protocol, with the endpoint to determine the role of mTORC1 and
autophagy in severity of pancreatitis, similarly showed a pattern of early autodegradation
followed by mTORC1 activation (Hu et al, 2015). The authors also found that rapamycin
worsened severity of pancreatitis. In liver, it has long been known that the earliest phase of
hepatocyte response to partial hepatectomy is massive activation of autophagy/lysosomes
(Becker & Lane, 1965). mTORC1 is required for the later stages of the process, when
proliferation is maximal, consistent with observations we make in the current manuscript (Jiang
et al, 2001; Nelsen et al, 2003; Buitrago‐Molina et al, 2009; Espeillac et al, 2011). In kidney, the
reprogramming process involves mTORC1 (Kato et al, 2012), and we show here that mTORC1
activity is increased specifically in the tubular cells, which are the cell population called back
into the cell cycle to regenerate damaged tissue. To our knowledge, lysosomes/autophagy has not
been examined in regenerating kidney. In mature glial cells that dedifferentiate following axonal
injury, activation of autophagy/lysosomes is a well‐established early event (Jessen & Mirsky,
2016). To our knowledge, mTORC1 activity has not been examined in the process. Furthermore,
in tissue culture cellular reprogramming models to generate induced pluripotent stem cells, there
is an emerging literature that an early autophagy phase is followed eventually by mTORC1
activation. Inhibition of either autophagy or prolonged inhibition of mTORC1 reduces
reprogramming efficiency (He et al, 2012; Wang et al, 2013; Wu et al, 2015). Hence, the stages
and checkpoints appear to be the same as the ones we examine in the current manuscript.

Thus, there are numerous reports indicating that the pattern we show here systematically
of autodegradation first, then mTORC1 activation may be universal. Moreover, teleologically, it
makes sense that a mature cell would first recycle cellular components required for physiological
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function to use them as substrates for subsequent synthesis of components needed for
proliferation. In organs like the vertebrate pancreas or liver, where there are no constitutively
active stem cells, repair would likely depend in large part on paligenosis. In tissues with
constitutive stem cells, like stomach and intestines, the tissues would have the choice of
regenerating with either constitutive stem cells or paligenotic cells, depending potentially on
type, extent, and location of injury.

Not all differentiated cells are likely to be able to undergo paligenosis. In the stomach, for
example, we have never observed this phenomenon in mature parietal cells (Huh et al, 2012;
Mills & Sansom, 2015). Cells that are constitutively undifferentiated and replicative like those of
the isthmus of the stomach or LGR5+ crypt‐base columnar cells should not need any stage of
paligenosis (Fig 7). They may acquire the building block nucleotides and amino acids from the
blood and/or extracellular environment, given that, by definition, their lack of differentiation
means they contain limited non‐nuclear components to recycle. Other cells, such as mucous neck
cells in the stomach or +4 cells in the intestine (van Es et al, 2012; Roth et al, 2012; Buczacki et
al, 2013), may be able to respond to injury but are less well differentiated and thus may be able
to skip the autodegradative phase and go directly to the activating mTORC1 and cell division
phase of paligenosis.

Paligenosis may be beneficial for its potential to provide lifelong tissue repair in adult
organs, but this capacity also seems inherently tied to increased risk for tumorigenesis. Chronic
injury of the type that repetitively induces paligenotic/metaplastic events has long been known to
increase risk for acquisition of mutations and progression to neoplasm. We have proposed that
the reason that risk increases with age is that cycles of paligenosis and subsequent
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redifferentiation allow accumulation of mutations that may be stored in long‐lived, differentiated
cells. Eventually, a critical mutation may be unmasked during paligenosis, and a clone of cells
that is unable to redifferentiate arises. We have termed this the “cyclical hit” model of
tumorigenesis (Mills & Sansom, 2015; Saenz & Mills, 2018).

There are numerous questions that our current study prompts. What molecular events
underlie the competence to pass through each stage of paligenosis? What is the relationship
between paligenosis and chronic injury, and what causes the increased risk for cancer? Why are
some cells able to undergo paligenosis, whereas others are not? We expect that the framework of
sequential phases of paligenosis that we introduce here, along with the potential checkpoints that
serve as molecular barriers between each stage of the process, can serve as a starting point for
future questions.

Chapter 2.4 MATERIALS AND METHODS

Animal studies and reagents

All experiments using animals followed protocols were approved by the Washington
University School of Medicine Animal Studies Committee. WT C57BL/6 mice were purchased
from Jackson Laboratories (Bar Harbor, ME). Tg(Atp4b‐cre)1Jig/JcmiJ (Atp4b‐Cre) (Syder et al,
2004), Gt(ROSA)26Sortm4(ACTB‐tdTomato,‐EGFP)Luo/J (ROSA26mtmg) (Muzumdar et al,
2007), Gnptab (Gelfman et al, 2007),and LC3‐GFP (Mizushima et al, 2004) mice were
previously described. Gnptab mice were a kind gift from Dr. Stuart Kornfeld of Washington
University. Tamoxifen (5 mg/20 g body weight; Toronto Research Chemicals) was injected
intraperitoneally (IP) daily for 2–3 days to induce maximal gastric injury (Huh et al, 2012; Saenz
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et al, 2016). Tamoxifen was prepared by first dispersing in 100% ethanol by sonication and then
emulsifying in sunflower oil (Sigma‐Aldrich) 9:1 (oil:ethanol). Pancreatitis was induced by 6
hourly IP injections of 50 μg/kg (in 0.9% saline) cerulein (Sigma‐Aldrich) given every other day
for up to 2 weeks. Mice were sacrificed 24 h after the final cerulein injection. Rapamycin (60
μg/20 g body weight; LC Laboratories) was injected IP in 0.25% Tween‐20, 0.25% polyethylene
glycol in PBS for 3–7 days prior to starting and throughout injury time course. Tunicamycin
(Carlisle et al, 2014) and two‐thirds partial hepatectomy (Blanc et al, 2010) injuries were
performed as previously described. Mice were given an IP injection containing 5‐bromo‐2′‐
deoxyuridine (BrdU; 120 mg/kg) and 5‐fluoro‐2′‐deoxyuridine (12 mg/kg) in sterile water 90
min before sacrifice for all BrdU labeling experiments.

For parietal cell isolation, stomachs were harvested and washed several times with PBS.
The forestomach and antrum were carefully removed and the remaining corpus minced with a
razor blade. The tissue was mechanically dissociated using a 50 μm Medicon (Beckman) for two
30‐s pulses. Chunks of tissue were further dissociated by incubating in 10 ml HBSS with 5 mM
EDTA and 1 mM DTT with vigorous shaking for 1 h at 37°C, and then, the solution was run
through a 100‐μm filter. Single cells were allowed to rest at 37°C, while filtered chunks were
incubated in 10 ml RPMI 1640 with 5% BSA (Sigma) and 1.5 mg/ml Dispase II (Stem Cell
Technologies) with vigorous shaking for 1.5 h at 37°C and then filtered again. Dissociated cells
were pelleted and washed with cold HBSS three times and then resuspended in PBS with 1%
BSA and 5 mM EDTA. Cells were sorted into a parietal cell population (GFP) and all remaining
cells (tdTomato) using a MoFlo FACS machine (Dako/Cytomation).
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Imaging and tissue analysis
Mouse tissues were immediately excised and flushed with phosphate‐buffered saline and
fixed overnight in 4% paraformaldehyde in PBS. Tissues were washed, embedded in 3% agar,
and then underwent routine paraffin processing. Sections prepared for immunofluorescence or
immunohistochemistry underwent standard deparaffinization and rehydration protocols, were
blocked in 5% normal serum, and left overnight with primary antibodies. Sections were washed
in phosphate‐buffered saline and incubated for 1 h with secondary antibodies and then washed
prior to mounting. For antibodies used in this study, see Appendix Table S2.
Immunofluorescence images were taken on a Zeiss Apotome or LSM710 confocal (Zeiss).
Bright field images were taken on a Nanozoomer (Hamamatsu) whole slide scanner or DP70
microscope (Olympus). Counting of stomach cell populations and proliferation was done as
previously described (Burclaff et al, 2017), except for analysis of Gnptab−/− mice. To account for
frequent gland loss in the base of these mice, a different approach was taken. For chief cell
quantification (SOX9+ and BrdU+), 10 random, 20× fields were chosen in three Gnptab−/− and
three control animals, and chief cells scored in slides from SOX9 or BrdU immunostained
sections. For BrdU, distribution, the 10 fields were further subdivided into two rectangular
regions: a basal one 100 μm perpendicular and 450 μm parallel to the muscularis mucosa and a
region of the same size immediately adjacent and encompassing the neck of the gastric unit. All
BrdU+ cells were scored and the proportion in each zone calculated. Quantification of
proliferation in the pancreas was done by counting 10 randomly sampled whole 20× fields per
condition. Cathepsin D+ area was calculated by generating a region of interest around PGC+
zymogenic cell cytoplasms and using particle counting analysis in ImageJ (NIH) to calculate
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Cathepsin D+ area relative to total cytoplasmic area. Tissue preparation and imaging for electron
microscopy was done as previously described (Ramsey et al, 2007).

Human tissue studies

Human gastric pathological tissue specimens were obtained with approval by the
Institutional Review Board of Washington University School of Medicine. Figure 3A is a
representative image from a qualitative analysis of 44 separate curated gastric clinical samples
that have been previously described (Lennerz et al, 2010; Radyk et al, 2018). The study of tissue
microarray cases included in this paper was also approved by the China Medical University First
Hospital Institutional Review Board and Ethics Committee. This patient cohort was initially
treated at the China First Medical University, and routine standard of care specimens was
obtained from patients treated between 2005 and 2009. Tumor, metaplastic, and uninvolved
normal tissue from each patient was formalin‐fixed and paraffin‐embedded. Staining was scored
on the following scale: 0, no staining; 1, minimal staining; 2, moderate to strong staining in at
least 20% of cells; 3, strong staining in at least 50% of cells. The scoring system was designed,
and independently verified, by a human pathologist.

Bioinformatics, microarray, qRT–PCR, and statistical analyses

For qRT–PCR and microarray analyses of mouse stomach ±rapamycin, two independent
experiments were run and a total of two to three separate mice and corresponding microarrays
were generated for each condition. All mice were harvested 3 days after first injection and
treated as per protocol in (Fig EV1). Conditions were Veh‐Veh (rapamycin vehicle regimen + 3
days of tamoxifen vehicle), Veh‐Tam (3 days of rapamycin vehicle regimen + 3 days of HD‐
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Tam), Rap‐Veh (rapamycin regimen, 3 days of tamoxifen vehicle); Rap‐Tam (rapamycin
regimen + 3 days of HD‐Tam). RNA for microarray and qRT–PCR analysis was isolated as
previously described (Lo et al, 2017). For microarray, samples were processed and hybridized to
Affymetrix Mouse Gene 2.0 ST per the manufacturer's instructions by the Washington
University Genome Technology Access Core (GTAC). GeneChips were analyzed with Partek
Genomic Suite 6.6 (Partek, Inc.) analysis software using default settings (Lo et al, 2017).
Mapping to Gene Symbols was done either via GSEA (Subramanian et al, 2005) or GenePattern
software (Reich et al, 2006). GSEA was done using default 3.0 settings. GMX files were made
using previously published microarray data in the case of laser‐capture micro‐dissected chief
cells (Capoccia et al, 2013), generated de novo or acquired from GSEA molecular signatures
database. For the list of parietal cell‐specific genes generated de novo for the current manuscript,
flow cytometry was used to sort parietal cells and control cells into 500 μl RNA protect reagent
(Qiagen). RNA was isolated using the RNeasy Micro Kit (Qiagen) following the manufacturer's
instructions. Mouse Gene 2.0 ST Array (Affymetrix) was used to analyze gene expression, and
the gene set whose expression was enhanced at least eightfold (96 separate genes) in parietal
cells vs. control was determined by Partek. For primers used in qRT–PCR, see Appendix Table
S3. Statistics for cell counts and qRT–PCR were done by Student's t‐test (in the case of pair‐wise
analysis of significance) or ANOVA (if multiple conditions were compared). For determining
statistically significant differences among various conditions in ANOVA, the post hoc tests were
either Tukey's (for multiple crosswise comparisons of means) or Dunnett's (for comparisons of
multiple experimental samples to a single control). For the tissue microarray, a χ2 analysis was
performed.
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Western blot

Approximately 100 mg mouse corpus stomach tissue was lysed in urea buffer (8 M urea,
1% SDS, 150 mM Tris–HCl, pH = 7.0) with 1× protease/phosphatase inhibitor cocktail
(Thermo). Protein concentration was determined using the DC protein assay (Bio‐Rad). Protein
(30 μg) was separated using a 10% SDS–PAGE gel and transferred to PVDF membranes
(Millipore). Membranes were incubated overnight at 4°C with Rabbit polyclonal pS6 240/244 or
235/236 (1:1,000 diluted, CST) and Rabbit polyclonal beta‐tubulin antibody (1:1,000 diluted,
CST) and then incubated with infrared fluorescent dye‐conjugated secondary antibodies (LI‐
COR Biosciences). Protein signal intensities were normalized against a tubulin loading control
for each sample. Fluorescent intensity values were determined and quantified on Western blots at
non‐saturating exposures using the ImageJ software. Statistical analysis with both antibodies was
done using ANOVA with a post hoc Dunnett's test.
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68

Appendix Figure S2.1

Appendix Figure S1 - GSEA of microarray data shows that Rapamycin does not affect
injury induced changes in parietal and chief cell gene expression but causes aberrant
expression of a cohort of genes typically induced in SPEM.
A, B GSEA and Genechip analyses were performed as for Fig.4, except panels A and B depict
comparisons of a parietal cell specific gene set performed by flow cytometric purification of
parietal cells (see Methods) with panel A showing how parietal cell gene expression is greatly
enriched in vehicle control vs. HD-Tam and panel B showing that adding rapamycin with or
without HD-Tam does not affect this pattern.
C Direct comparison of rapamycin+HD-Tam vs. HD-Tam shows that loss of parietal cell gene
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expression after HD-Tam treatment is not affected by rapamycin; if anything, rapamycin causes
even more parietal cell injury as there is some enrichment of parietal cell gene expression in HDTam alone.
D Previously published chief cell-specific gene set also shows no relative enrichment in HDTam vs. HD-Tam+rapamycin, indicating chief cell paligenosis is not affected by rapamycin.
E On the other hand, a previously published SPEM gene set shows enrichment in a specific
subcluster of genes in HD-Tam vs. HD-Tam+rapamycin, indicating rapamycin blocks induction
of a certain subset of SPEM genes.IM, intestinal metaplasia; pSPEM, proliferative SPEM;
qSPEM, quiescent SPEM.
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Appendix Figure S2.2

Appendix Figure S2 - LAMP1 time course during cerulein injury shows a pattern of
increased then decreased activation similar to that of stomach.
Upon injury LAMP1 vesicles are induced in acinar cells starting around 8 hours and peak around
24 hours. By 3 to 5 days, the vesicles in exocrine cells begin to decrease back towards levels
seen at homeostasis. Boxes in top panels are magnified to highlight acinar cells in bottom panels.
Scale bars:20 μm

71

Appendix Figure S2.3

Appendix Figure S3 - Gnptab−/− acinar cells after 2 week cerulein treatment remain
cryptically acinar.
A Comparison of amylase staining between Gnptab−/− and Gnptab−/+ following 2 weeks of
cerulein treatment. In Gnptab−/− tissue, only scattered acinar cells remain highly positive for
amylase (red arrowhead), with the vast majority only retaining weak positivity (yellow
arrowheads). Scale bar: IF, 20 μm; IHC, 50 μm.
B Survey of metaplasia (CK8/18), mature acinar (GATA4), and epithelial markers (E-cadherin)
on Gnptab−/− tissue. Gnptab−/− acinar tissue does not stain for the metaplasia marker CK8/18 or
the mature acinar nuclear marker Gata4. The poorly differentiated acinar cells are positive for Ecadherin. Scale bar: IF, 20 μm; IHC, 50 μm.
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Appendix Figure S2.4

Appendix Figure S4 - Apoptotic cells death during HD tamoxifen or cerulein-induced
injury.
A At HD tamoxifen day 3 with or with rapamycin treatment, the stomach epithelium lacks
apoptotic cells, indicating the main atrophy stage – in which parietal cells, but not chief cells, die
by apoptosis –occurred earlier. In Gnptab−/− tissue, apoptotic cells can be found located at the
base of some units consistent with the increased dropout of basal cells described in the results.
Scale bar, 100 μm.
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B During Cerulein at day 5, scattered apoptotic cells are seen in all experimental conditions,
indicating the atrophy in this more asynchronous injury model is still occurring during this time
window. No qualitative increase in cleave caspase positive cells were seen in rapamycin or
Gnptab−/− tissue. Scale bar, 100 μm.
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EXPANDED VIEW FIGURE 2.1
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Figure EV1. pS6 is an accurate proxy for rapamycin-sensitive mTORC1 activity and shows that
loss of mTORC1 does not affect parietal cell death or induction of metaplastic gene expression
in reprogramming chief cells. A Injection schemes for injury experiments with rapamycin in
stomach (left) and pancreas (right). B Representative epifluorescence images of the distribution
of pS6 in the normal and injured stomach rapamycin treatment. pS6 is restricted to the chief cell
zone (base) and pit zone of the normal corpus unit. At peak (HD-Tam day 3) SPEM stages, it is
located at high level throughout the unit. Upon rapamycin treatment, all pS6 staining is lost
throughout the normal and injured corpus unit. The characteristic induction of GSII staining in
reprogramming chief cells at the base of gastric units (indicating SPEM) occurs at least as
markedly in the presence of rapamycin, indicating mTORC1 is not required for metaplastic gene
induction. Green, pS6; white, GSII; blue, DAPI. Scale bars: 50 m. C At peak metaplasia stages,
pS6 235/6 is upregulated in the stomach epithelium and rapamycin treatment at this stage
abolishes all staining. Scale bars: 50 m. D Representative epifluorescence images of the loss
parietal cells (marked by ezrin) upon injury and rapamycin treatment. Treatment with HD-Tam
caused the loss of the vast majority of parietal cells throughout the corpus. Rapamycin does not
rescue that injury. Green, GSII; white, ezrin; blue, DAPI. Scale bars: 50 um.
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EXPANDED VIEW FIGURE 2.2
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Figure EV2. Acute kidney injury and partial hepatectomy both cause upregulation of mTORC1
activity during proliferative phases.
A Upon injury with tunicamycin, tubule cells in the kidney are damaged (white arrowhead) and
surviving tubule cells (yellow arrowhead) upregulate pS6. Scale bars: 100 m.
B Upregulation of the pS6 is associated with increased proliferation in this injury model as seen
by BrdU+ nuclei. Scale bars: 100 m.
C Two-thirds partial hepatectomy causes a pronounced upregulation of pS6 in the remaining
hepatocyte mass. Scale bars: 20 m.
D The pS6+ hepatocytes are highly proliferative at this stage. Scale bars: 20 m.
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EXPANDED VIEW FIGURE 2.3
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Figure EV3. Histological changes in the injured stomach and pancreas with and with rapamycin
treatment.
A Representative hematoxylin and eosin counterstained images of HD-TAM stomach tissue
rapamycin. Treatment with tamoxifen causes acute loss of parietal cells (large eosinophilic cells)
by 12–24 h post-injury. By 3 days, chief cells have reprogrammed into SPEM cells. The general
pattern of loss of parietal cells and conversion of chief cells to metaplastic cells is not affected by
rapamycin (right panels). Scale bars, 50 m.
B Representative hematoxylin and eosin counterstained images of pancreas tissue injured with
cerulein at various stages rapamycin. Cerulein injury causes mosaic, asynchronous conversion of
acinar cells into proliferative, acinar-ductal metaplastic cells with maximal features of the
process at day 5 in our protocol. By 2 weeks, the pancreas has compensated for the continuous
injury and recovers a relatively normal morphology. Dual treatment with rapamycin and cerulein
does not rescue the metaplastic response by day 5 and impedes normal tissue compensation by 2
weeks injury, with most of the tissue continuing to show abundant metaplastic forms. Scale bars,
50 m.
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EXPANDED VIEW FIGURE 2.4
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Figure EV4. mTORC1 is not required for increased SOX9 during metaplasia.
A Representative eosin counterstained IHC images of normal or metaplastic gastric tissue stained
for SOX9. SOX9, in control tissue, stains the isthmal and mucous neck cells, which are
proliferative progenitors (yellow arrowheads), of the corpus units and is generally excluded from
the base of units. Upon injury with HD-TAM, SOX9 expression is induced in the base of units
(yellow arrowheads). Treatment with rapamycin does not alter either the normal or metaplasia
distribution of SOX9 (yellow arrowheads). Scale bars, 50 m.
B Representative hematoxylin counterstained IHC images of normal or metaplastic pancreatic
tissue stained for SOX9. SOX9 expression in normal pancreatic tissue is restricted to the duct
(see inset in top left panel which is a high magnification view of the boxed area). At peak
metaplasia stages, SOX9 becomes expressed in dedifferentiating acinar cells (see bottom left
inset). Treatment with rapamycin in normal (see top right inset) or injured (see bottom right
inset) does not alter SOX9 expression. Scale bars 50 m; inset 25 m.
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EXPANDED VIEW FIGURE 2.5

Figure EV5. Representative IHC images from human tissue microarray.
A Intestinal metaplasia (“IM” indicating the glands to upper left of red dashed line) is generally
proliferative as evinced by frequent Ki-67+ cells (left) and is strongly pS6 positive. Most SPEM
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has a quiescent phenotype (glands labeled on “qSPEM” side of panels) characterized by cells
with abundant mucus, flattened basal nuclei, and a lack of both Ki-67 and pS6 staining Scale bar,
200 m.
B Rare SPEM lesions show cells with cuboidal columnar morphology. These lesions show Ki-67
positivity usually associated with pS6 positivity. Boxed regions are shown at higher
magnification below. Scale bar, 200 m; pullout, 50 m.
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EXPANDED VIEW FIGURE 2.6
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Figure EV6. Histological appearance of Gnptab-/- stomach and pancreas tissue at injury time
points.
A Representative hematoxylin and eosin counterstained images of Gnptab+/- and Gnptab-/stomach tissue. Gnptab-/- chief cell cytoplasms have a hypertrophic, frothy appearance compared
to control zymogenic cells. Loss of parietal cells (fried-egg appearing eosinophilic cells)
following HD-Tam is not affected by loss of GNPTAB; however, the base zones in Gnptab-/mice at day 3 HD-Tam are usually resistant to dedifferentiation (red arrowheads) with large,
frothy chief cells remaining largely non-reprogrammed. Another, less common phenotype is that
all chief cells are lost such that most of the base of the unit disappears (green arrowheads). Rare
units partially undergo morphological metaplastic changes, though usually those are also
associated with loss of basal cells (yellow arrowheads). Higher magnification
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views are to right of each panel, with white bracket delineating particular region of interest in
Gnptab-/- stomach Scale bar 50 m; pullout, 25 m.
B Representative hematoxylin and eosin counterstained images of Gnptab-/+ and Gnptab-/pancreas. Similar to the stomach zymogenic cells, pancreatic acinar cells also have a
hypertrophic, frothy appearance. Whereas control samples treated with cerulein show diffuse,
asynchronous acinar-to-ductal metaplasia, Gnptab-/- mice have acinar cells that simply become
less eosinophilic and foamy over time without undergoing ADM. By 2 weeks, wild-type
pancreas has largely adapted to cerulein, whereas Gnptab-/- pancreas parenchyma comprises only
lobules of excessively pale (hyaline), frothy acinar cells and scattered reactive ducts. Scale bar
50 m; pullout, 25 m.

90

EXPANDED VIEW FIGURE 2.7

Figure EV7. Lysosomal activity is required to reactivate mTORC1 following HD tamoxifen
injury.
A At peak metaplasia stages in Gnptab-/+ tissue, pS6 is re-expressed throughout the stomach
epithelium, including intense staining within the pit and metaplastic base. Scale bars: 50 m;
pullout, 25 m.
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B In Gnptab-/- issue, pS6 is not reactivated in the base, indicating lysosomal activity is required
for mTORC1 re-activation at later stages following injury. Boxed regions are shown at higher
magnification at right with a representative base (in which pS6 remains inactive without
lysosomal activity) outlined by dotted line. Lysosomal activity appears dispensable for pit cells
(at top of gastric unit) mTORC1 activity. Scale bars: 50 m; pullout, 25 m.
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Chapter 3.1 INTRODUCTION
Colorectal cancer (CRC) is the third most common cancer in the world, and the global
burden is expected to increase due to the growth and aging of the population. Despite advances
in diagnosis and therapy, CRC remains the third most common cancer related cause of death in
the United States among men and women, and the overall 5-year survival rate is 65% [1], and
[1]. Colon cancer is a biologically heterogeneous disease that develops via distinct pathways
involving combinations of genetic and epigenetic changes. Defining tumor subtypes based upon
pathway-driven alterations has the potential to improve prognostication and guide targeted
therapy [2]. However, it has become increasingly clear that there is marked heterogeneity in the
“driver gene” mutational profiles within and among colon cancers. Some of these mutations are
also found in non-tumor tissue [3], and are not sufficient to explain differences in colon cancer
behavior and tumor response among patients [4]. Changes in the tumor landscape which may
involve global modulation of gene expression have been suggested to play a role in these
processes [4].
Interferon-related development regulator 1 (IFRD1, aka mouse Tis7, PC4) is a
transcriptional co-regulator with a putative role in regulating intestinal lipid metabolism and
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epithelial cell proliferation [5]. Expression of IFRD1 is increased in injury states in multiple
organ systems, such as after massive intestinal resection [6], nerve [7] and muscle [8, 9] injury.
Analysis of the intracellular localization of IFRD1 in cultured cells demonstrates cytoplasm or
nuclear localization depending on the cellular differentiation state [10]. This suggests that the
immediate early gene IFRD1 may function in the cytoplasm as a sensor of cellular stimuli, and in
the nucleus as a transcriptional modifier. In the nucleus IFRD1 has been shown to interact with
the SIN3 protein complex, scaffold histone deacetylases [11], and regulates the expression of
large gene cassettes in epithelial cells, myoblasts, hematopoietic cells, and neurons [12]. Review
of the expression patterns of IFRD1 in 79 human tissues revealed that it is ubiquitous but
particularly abundant in colorectal adenocarcinoma as well as in whole blood, testis, olfactory
bulb, pancreas and other highly secretory tissues [13]. IRFD1 expression is increased in multiple
cancers, as shown in large scale genomic/proteomic colon cancer analyses (including
TCGA/Protein Atlas) [14, 15]. We have shown that IFRD1 expression is increased up to
eightfold in the repairing small intestine following gut resection, and it is associated with a
marked increase in gut epithelial cell proliferation [16]. Conversely, loss of IFRD1 inhibited the
crypt cell proliferative adaptive response after massive intestinal resection [6].
Herein we aimed to explore the role of IFRD1 in human colon cancer pathogenesis.
Specifically, we address the hypothesis that, given IFRD1’s role in driving stress-induced
proliferative response, increased IFRD1 expression in colon cancers would be associated with
reduced survival. IFRD1 expression patterns of 378 human colon cancers and normal adjacent
colon epithelium were analyzed by immunohistochemical analysis. We used a large,
international multicenter, ethnically and racially diverse patient cohort to investigate how IFRD1
expression correlates with tumor severity, patient clinical demographics and overall survival.
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Chapter 3.2 METHODS
Subjects
Formalin-fixed paraffin-embedded tissue (FFPE) from colon cancer (or colorectal
carcinomas) and normal colonic mucosa from patients of three institutions from the United
States, Spain and China were used for this analysis. The American cohort of colon cancer
patients (n=72) were randomly selected from a subset of the Oncology Data Service cancer
registry treated between 01/01/1999 and 06/30/2003 at the Barnes-Jewish Hospital in St. Louis,
Missouri, a tertiary care institution affiliated with the Washington University School of Medicine
Siteman Cancer Center. Data in the cancer registry includes demographic, clinical, and survival
data in accordance with the American College of Surgeons Commission on Cancer guidelines.
Pathological and surgical data was extracted from the medical chart. The Spanish cohort
consisted of 227 consecutive stage II-III colon carcinoma patients obtained from Hospital Clinic,
University of Barcelona, Barcelona, Spain, treated between 1993 and 2006 and, subjected to
curative-intent surgical resection from 1998 to 2005. All cases were anonymized and the study
was approved by the Hospital’s Institutional Review Board and Ethics Committee. Patients were.
The Chinese cohort of colon cancer patients (n=??), treated at the China Medical University
between 2005 and 2009, were also anonymized and the study was approved by the China
Medical University First Hospital Institutional Review Board and Ethics Committee. TNM stage
was determined for all patients.
Immunohistochemistry
Tissue microarray (TMA) sections containing representative cores from FFPE tissue from
tumor and normal mucosa of all patients were used for immunohistochemistry (IHC) staining.
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Two tumor sections from each patient were selected based on tissue quality and were used to
score tumor staining. Monoclonal antibody anti-Tis7/IFRD1 (Sigma-Aldrich, St. Louis, MO;
1:500) was incubated overnight on deparaffinized 2-4 µm thick TMA sections after decloaking
with Diva antigen retrieval buffer (Biocare, Concord, CA). Antigen-antibody complexes were
detected using biotinylated secondary antibody and streptavidin-horse radish peroxidase.
We used the H-score for IHC staining analysis. Three trained independent observers and
a pathologist (JCM) graded the intensity of immunostaining of the tumors and normal mucosa on
a 4-category scale of 0-3. The histological scoring system and individual specimen scoring were
supervised by a pathologist (JCM). A score of 0 was assigned for no anti-Tis7/IFRD1 staining, a
score of 1+ for traces or scattered staining in otherwise negative tumors, a score of 2+ for
uniform staining of the entire tumor with light brown intensity, and a score of 3+ for uniform
staining of the entire tumor with intense brown staining. The final score was the mean of the
scores from the individual observers.
Statistical Analysis
The association between IFRD1 expression with other demographic/clinical characteristics
was assessed using Chi-square Nonparametric test. The primary clinical outcome was overall
survival (OS) which was defined as the time from diagnosis to death due to cancer, and survivors
were censored at the date of last contact. Kaplan-Meier method and Log-rank analysis were used
to assess the association between IFRD1 expression and OS, while adjusting potential confounding
effects of other demographic/clinical characteristics. Cox regression analysis was used to
determine the independent effect of each variable on patient survival. All analyses were two-sided
and significance was set at a p-value of 0.05. Statistical analyses were performed using SPSS 19.0.
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Chapter 3.3 RESULTS
Patient Characteristics
Colon cancer specimens from 378 patients from the United States (n=72), Spain (n=105)
and China (n=201) were analyzed by IHC staining for IFRD1 expression. The average age for
the entire patient cohort was 66 years (Supplemental Table 1). There were 194 males and 184
females. Of 378 colon cancers, 6% were TNM stage I, 45% TNM stage II, 45% TNM stage III
and 4% TNM stage IV.
The final IFRD1 staining score was the mean of the staining intensity scores of three
independent observers as defined in the Methods. IFRD1 immunoreactivity scores were based
on the intensity of stain (Figure 1A-1D). Overall, 36.2% of the tumors had a score of 0-1 (low)
and 63.7% had a score of 2-3 (high) (Table 1).
IFRD1 expression is increased in colon adenocarcinomas compared to normal colon
epithelium.
Normal colonic mucosa demonstrated no or minimal IFRD1 immunoreactivity (Figure
1E). When present in normal mucosa, staining was low in intensity, scattered and localized in the
nuclei of crypt enterocytes with minimal cytoplasmic immunoreactivity (Figure 1E inset). In
contrast, almost all (373/378, 98.7%) of the colorectal cancers showed evidence of readily
detectable IFRD1 expression (Figure 1B-D). Immunoreactivity was localized predominantly in
the tumor cytoplasm (Figure 1B, C), with nuclear staining detectable in tumors with highintensity, 3-score (Figure 1D). Tumor groups at the infiltrating border tended to exhibit more
intense immunoreactivity (Figure 1F).
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Most patients were 60 years or older at the time of diagnosis (69.8%, 264/378, Table 1).
There was a significant association between age and IFRD1 immunostaining intensity,
comparing patients < 60 or ≥ 60 and tumors with low vs. high expression (p = 0.013). There was
no significant association with gender.
We also found a significant relationship between tumor location, i.e.: right vs. left colon,
and levels of IFRD1 expression (Table 2, p=0.036). Seventy percent of right sided tumors had
high IFRD1 expression compared to 59% of left sided tumors. TNM stage and IFRD1
expression showed no association (Table 2).
Increased IFRD1 expression in colon cancers is associated with reduced five-year patient
survival.
High IFRD1 colon cancer expression (score 2-3) correlated with decreased 5-year overall
survival (Figure 2, p=0.025). Subgroup analysis showed that patients in the American cohort
with high IFRD1 colon cancer expression had a poorer prognosis and reduced 5-year survival
compared to patients in the Chinese or Spanish cohorts (p<0.001; Fig. 3). There was a
significant relationship among the three cohorts with high IFRD1 expressing tumors for age
(p=0.011, Table 3) gender (p=0.007; Table 3) and tumor location, but not TNM stage (Table 4).
There were more right-sided tumors in the Chinese cohort, more left-sided tumors in the Spanish
cohort and a relatively equal distribution of right and left sided tumors in the American cohort
(p=0.001; Table 4).
On the multiple regression analysis, the levels of IFRD1 expression were not related to
survival (Table 5). As expected, TNM stage (p<0.001; Table 5) independently predicted patient
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survival. In addition, country of origin (p<0.001; Table 5) independently predicted patient
survival.
Chapter 3.4 DISCUSSION
In the present study, we show that expression of the transcriptional co-regulator IFRD1 is
increased in colon carcinomas compared to normal colon mucosa, and on the univariate analysis
patients with high IFRD1-expression colon cancers have a reduced 5-year survival compared to
patients with low IFRD1-expression. IFRD1 expression also correlated significantly with tumor
location, being higher in right-sided carcinomas. The prognosis of right sided colon cancer is
significantly worse than those in the left [17], thus, reduced survival associated with high IRFD1
expression and the higher percentage of right compared to left colon tumors with high IFRD1
expression suggest a role for IFRD1 as a modulator of increased tumorigenicity.
IFRD1 is a transcriptional co-regulator that interacts with the SIN3-histone deacetylase
(HDAC) complex which then binds to DNA promoter sites and regulates global gene
transcription [11] [12]. Depending on the cell type and context, IFRD1 may act as a
transcriptional co-repressor or co-activator [12] to regulate a variety of cellular processes include
cell proliferation and differentiation [8]. IFRD1 exhibits a low basal level of expression in
multiple organs and cell types in normal homeostasis; in contrast, its expression is highly
regulated in a wide variety of tissue injury models, suggesting a conserved role for IFRD1 in the
cellular response to injury and stress [6, 9, 18]. For example, in the intestine, we have shown that
IFRD1 plays a role in in regulating the adaptive increase in gut epithelial cell proliferation that
occurs in response to resection-induced injury [6]. Ifrd1-/- mice show a blunted response to
bowel resection with decreased crypt cell proliferation early after resection.
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IFRD1 expression is regulated by growth factors including NGF, FGF and EGF [16] and
glucagon-like peptide 2 [16]. IFRD1 also has effects on immune cell function and on tumor
immune surveillance and plays a complex role in NF-kB signaling [19]. IFRD1 has been shown
to regulate viral immune evasion mechanisms in human papilloma virus-induced keratinocytes
with similar effects in cervical cancer cell lines, via suppression of immune driven RelAassociated NF-kB cytokine expression mediated by the EGFR [20]; in this model, IFRD1 acts
downstream of the EGFR to deacetylate NFkB/RelA. In patients with cystic fibrosis who are
homozygous for the F4508 deletion mutation, IFRD1 was identified as a modifier of lung disease
via effects on neutrophil effector function [21]; in this study, IFRD1 deficiency was associated
with decreased NF-ĸB p65 transactivation, mediated by effects on NF-kB induced transcription
via HDAC. In contrast, IFRD1 is a repressor of NF-kB transcriptional activity in myoblasts via
recruitment of HDAC3 in a murine model of muscle regeneration following injury [19]. Finally,
IFRD1 deficiency increased p65 acetylation via inhibition of histone deacetylase-dependent
deacetylation in bone marrow macrophages, repressing NF-kB dependent transcription of
NFATc1 [22]. Thus depending on the cellular context and lineage, IFRD1 may increase or
decrease NF-kB dependent transcriptional activity [22]. In sum, the observed worse prognosis
for patients with high IFRD1 expressing colon cancers may result from alterations in multiple
pathways, including direct effects on tumor cell proliferation [16], facilitating tumor immune
surveillance evasion [20] or by changes in immune cell function [21].
We observed a worse prognosis for American patients with high IFRD1 expression
compared to Spanish or Chinese cohorts. Although we were unable to identify a specific causal
factor, our cohort has a high percentage of African Americans (55%) who exhibit a marked
disparity in outcomes in colon cancer [23, 24]. Black vs. white disparities in mortality are
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increased in each stage of disease but appear driven in large part by differences in late stage
disease [25]. Due to the limited number of African American patients in our entire study cohort,
we cannot determine whether increased IFRD1 expression in colon cancers is also significantly
associated with African American populations; this will be the subject of future investigation in a
larger cohort of American patients.
In summary, we have identified novel IFRD1 gene expression patterns in colon cancer
which suggest a role for IFRD1 in increasing tumorigenicity and contributing to a worse
prognosis. The precise mechanisms by which IFRD1 exerts its effects are unknown; the adverse
effect on survival associated with high IFRD1 expression suggests that understanding these
mechanisms may provide novel targets for colon cancer therapy.
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Chapter 3.5 FIGURES

FIGURE 3.1

Figure 1 IFRD1 immunohistochemical staining in colon carcinomas.
Tumors were analyzed for IFRD1 expression using an anti-IFRD1 monoclonal antibody. IFRD1
immunostaining intensity was quantified by scoring on a scale of 0–3. a Tumors with a score of 0
had no to minimal IFRD1 immunoreactivity. Scattered light staining can be observed in the
nuclei of well-differentiated tumors. b Immunohistochemical score of 1 showed light staining
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throughout the tumor or more intense, but scattered staining. c Uniform staining of the entire
tumor with medium intensity (score 2). d Uniform staining of the entire tumor with intense
brown staining, often associated with increased nuclear staining (score 3). e Comparison of
tumor and normal mucosal staining demonstrates that IFRD1 staining is readily detectable in
colon cancer, but adjacent, uninvolved mucosa shows no or minimal IFRD1 immunoreactivity.
When IFRD1 staining was detected in the uninvolved mucosa, it was low in intensity and
localized in the nuclei of crypt cells with minimal cytoplasmic immunoreactivity (Fig. 1e inset). f
Tumor clusters at the invasive margin show more intense staining.
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FIGURE 3.2

Figure 2 Reduced 5-year survival in patients with high IFRD1-expression colon cancers.
Censored patients with high IFRD1 expression in tumors significantly poorer survival at 5 years
post diagnosis compared to patients with tumors with low IFRD1 expression (* p = 0.025).
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FIGURE 3.3

Figure 3 American patients with high IFRD1-expressing tumors have reduced 5-year
survival compared to Chinese and Spanish patients. Five-year survival analysis was
performed for all patients with high IFRD1-expressing tumors from American, Chinese,
and Spanish cohorts. American patients with high IFRD1-expressing tumors had reduced
5-year survival compared to Chinese and Spanish patients with high IFRD1-expressing
tumors *** p\0.001).
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Chapter 4: IFRD1 promotes survival and
proliferation in the conserved cellular
regeneration program (paligenosis) by
suppressing p53
Mark A. Lewis, Zhi-Feng Miao, Dongkook Park, Jeffrey W. Brown, Charles Cho, Susan
Kennedy, Jianyan Lu, Marcus Mahar, Ilja Vietor, Lukas A. Huber, Nicholas O. Davidson,
Valeria Cavalli, Deborah C. Rubin, Jason C. Mills

Chapter 4.1 SUMMARY
The capacity for mature cells to reprogram into a proliferative, regenerative state is a
general feature of multicellular organisms and appears to proceed by a dedicated, evolutionarily
conserved program (paligenosis). The fundamental cellular energy sensor and regulator of
protein translation, mTORC1, is the central regulator of paligenosis. Here, we reasoned that, akin
to apoptosis and other cellular programs, genes likely evolved to regulate paligenosis. We
identified IFRD1 as a gene conserved throughout eukaryotes, upregulated by paligenosisinducing injury, but not required for homeostatic regulation of proliferation and differentiation.
IFRD1 was critical for the injury-induced recruitment of cells into the cell cycle in Drosophila
intestine and multiple mouse tissues. Ifrd1−/− mice showed decreased mTORC1-mediated
proliferation and increased apoptosis in gastric and pancreatic paligenotic cells. mTORC1
inhibition and Ifrd1−/−;Trp53−/− experiments showed that IFRD1 works largely by alleviating
p53 repression of mTORC1 reactivation during stage 3 of paligenosis. Our results identify the
first gene regulating the conserved cellular program that recruits mature cells for regeneration. A
p53-mTORC1 balance dictates whether paligenosis is successful, and mature cells reenter
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mitosis or whether it fails and cells die. Pro-paligenotic genes like IFRD1 might be harnessed to
increase cellular reprogramming to promote regeneration; alternatively, because recruiting old
cells with potential stores of somatic mutations increases risk for cancer, blocking paligenosis
might prevent or treat cancer.

Chapter 4.2 INTRODUCTION
Following large-scale injury, mature cells in pancreas and stomach use a common
program (termed paligenosis) to reenter the cell cycle and fuel tissue regeneration1. Here, we
hypothesize that paligenosis, akin to other cellular programs like apoptosis, will be governed by
a conserved set of genes. We expect such genes to be: a) ubiquitously induced upon paligenosiscausing injury, b) conserved across species, and c) dispensable for normal development or stem
cell homeostasis. Nearly all tissues, across numerous species, demonstrate examples of
cellular plasticity in response to injury. We recently proposed a shared cellular program by
which differentiated cells can change their fate to facilitate injury repair1. In our investigation of
gastrointestinal organs (stomach, pancreas, liver, and intestine), we believe that each has the
capacity to repair tissue damage through the recruitment of fully differentiated cells into a less
differentiated, proliferative state to replenish lost or damaged cells. We also proposed that this
process could be expanded to include other cells (kidney, neurons, etc.) because of the dynamic
mTORC1 activity and proliferative or regenerative capacity that these tissues exhibit following
injury. This cellular “reprogramming” to a proliferative, regenerative state can occur in
various contexts, such as when tissue undergoes metaplasia following injury. In the acute setting,
the metaplastic response appears to be a tissue repair mechanism and can be temporary, with full
restoration of normal tissue architecture. Accordingly, we have shown that differentiated cells in
the stomach and pancreas have the capacity to revert to the embryonic state, becoming mitotic
126

again to aid in tissue repair. In tissues with constitutively active stem cells, like stomach and
intestines, the tissues would have the option of regenerating with either constitutive stem cells or
recruited stem cells, depending potentially on type, extent, and location of injury.
Identification of genes that regulate this repair is crucial to understanding human
diseases that are dependent on this process and has the potential to lead to breakthroughs in
personalized medical treatment. We would hypothesize that a gene whose primary function is to
regulate reserve stem cell function would be dispensable for normal cellular activity, but be
called to action during an acute injury response.
Through an in silico screen, we have identified IFRD1 as such a gene. It is an immediate
early gene that was originally found to respond to mitogens such as TPA, EGF, c-Jun and FGF.
IFRD1 associates with the Sin3 complex and is, thus, reported to play a role as a transcriptional
co-regulator with a putative function in regulating intestinal lipid metabolism and epithelial cell
proliferation 2,3. We and others have shown IFRD1 is a highly conserved, transcriptional coregulator that: responds transiently and rapidly to cellular stimuli; is critical for induction of
proliferation in intestinal repair but is dispensable for normal stem cell activity; has
polymorphisms associated with gastric cancer; and elevated expression is associated with poorer
survival in colon cancer patients 3-6. IFRD1 levels positively correlate with the processes of cell
and tissue injury response and regeneration in humans, mice and in lower species, such as, S.
pombe and D. melanogaster. The activity of energy sensing protein mTORC1 governs
paligenosis in the stomach and pancreas. Analysis of tissues that depend on mTORC1 activity
following injury revealed that there are 8 genes that are acutely upregulated following injury.
Expanding the screen to lung and glial tissues reveals that Ifrd1 and Atf3 are two genes that may
be critical for this injury response across multiple tissues. We are currently investigating the role
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of Atf3 in our models of paligenosis and, herein, we will describe the requirement of IFRD1 for
the proliferative response of reserve stem cells across multiple tissues and species.
Following large-scale injury, mature cells in pancreas and stomach use a common
program (termed paligenosis) to reenter the cell cycle and fuel tissue regeneration1. Here, we
hypothesize that paligenosis, akin to other cellular programs like apoptosis, will be governed by
a conserved set of genes. We expect such genes to be: a) ubiquitously induced upon paligenosiscausing injury, b) conserved across species, and c) dispensable for normal development or stem
cell homeostasis.
Chapter 4.3 RESULTS AND DISCUSSION
IFRD1 is highly conserved and is upregulated following regeneration-inducing injury in
multiple tissues and species
To identify tissue-independent paligenosis-regulating genes, we screened for mRNAs
whose expression was induced following injury in all 4 organs we previously used to delineate
the core paligenotic cellular response (stomach, pancreas, liver, kidney)1. We identified 8 genes
and determined if they were also increased in two additional injury-induced gene expression
profiles from tissues: lung and neural glia 7 8 that also are known to undergo dramatic, injuryinduced reprogramming (Fig. 1 a, b). Only two genes were upregulated in all 6 tissues: Ifrd1 and
the transcription factor Atf3 (Fig. 1b). Atf3 is the subject of ongoing work in our group; we focus
here on IFRD1.
We next tested if IFRD1 structure and function exhibited broad evolutionary
conservation. Our multisequence alignment of IFRD1 orthologs demonstrated conservation of
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nearly the entire protein from humans to the fission yeast Schizosacchromyces pombe (Fig. 1c
and Supplementary Fig. 1a). Our secondary structure prediction suggested extensive alphahelical character with the mature protein likely obtaining an armadillo (or alpha-solenoid) fold, a
structural motif used by other important scaffolding/signaling proteins like -catenin (CTNNB1)
and Adenomatous Polyposis Coli (APC). (Fig. 1c and Supplementary Fig. 1a). Further, a
cryoEM structure of IFRD2 bound to the ribosome demonstrates that the homolog assumes an
armadillo fold and secondary structure consistent with our unbiasedly prediction from the IFRD1
sequence (Supplemental Figure 1b). The yeast ortholog of IFRD1 (SPBC20F10.03) has not been
specifically characterized, but mRNA and protein screens detailed at PomBase 9 showed that its
expression increases following multiple stresses including H2O2 and heat but does not change
during normal cell cycle progression. Further, yeast null for the gene encoding IFRD1 do not
seem to have a vegetative/cell cycle defect, suggesting that the protein is specific to stress
response.
As in yeast, the Drosophila melanogaster ortholog of IFRD1, CG31694, has not been
specifically characterized; however, again, examination of various published screens showed that
difrd1 is upregulated during stem-cell-recruiting injury in the gut in response to
entomopathogenic Pseudomonas bacteria and implicated in the stem-cell recruiting Unpaired
(orthologous to IL-6) pathway 10. We confirmed that difrd1 increased following intestinal stemcell-recruiting stress using a strain expressing GFP under the difrd1 promoter (Fig. 1d).
Furthermore, whereas stem-cell-recruiting stress caused wildtype fly intestines to markedly
increase proliferation as expected, two strains hypomorphic for difrd1 failed to respond (Fig. 1e).
As the hypomorphic strains showed no defects in normal development or stem cell homeostasis,
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the regulation of proliferation by IFRD1 in Drosophila appears specific to situations where stem
cells are recruited after stress.
Previous studies by us and others have shown that in the absence of IFRD1, mice, like
yeast and flies, do not have substantial defects in development or adult organ stem cell
homeostasis (3 11, unpublished observations, Supplementary Fig. 3 b-e). We investigated a cellautonomous role for IFRD1 in two tissue types not represented in our initial screen. We
generated organoids from the small intestine. The efficiency of organoid establishment is a
function of how many stem cells can be recruited to grow in the ex vivo environment 12 13 14.
Enteroid forming efficiency and growth 7 days after passage were both significantly reduced in
the absence of IFRD1 (Supplementary Fig. 2 a-d). In parallel, we used a well-characterized
system that induces nuclear reprogramming of neurons along with expression of IFRD1:
axotomy of ex vivo grown dorsal root ganglion neurons 15,16. When IFRD1 was knocked down,
the reprogramming-dependent regeneration of axons was significantly compromised
(Supplementary Fig. 2c).
Therefore, IFRD1 is required for paligenosis and is: a) expressed in ubiquitous cell types
undergoing paligenosis; b) broadly conserved across eukaryotes; and c) dispensable for normal
homeostatic growth or development.
IFRD1 is required for stage 3 of paligenosis
We next wanted to explore where IFRD1 acted during paligenosis. We turned to the
injury models that we and others have shown induce canonical, three-stage paligenosis: highdose tamoxifen (HD-TAM) for the stomach and injection of the cholecystokinin analog cerulein
for the pancreas (1 Figure 1 A, B). We analyzed effects of loss of IFRD1 during the sequential
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stages of paligenosis: 1) autodegradation (when lysosomes and autolysosomes recycle existing
cell architecture); 2) induction of embryonic/progenitor gene expression; and 3) cell cycle reentry (Supplementary Figure 3a; 1).
Injury to both organs caused the expected metaplastic responses in wildtype control mice.
Gastric chief cells in the stomach became cuboidal-columnar cells characteristic of the
differentiation pattern known as Spasmolytic Polypeptide Expressing Metaplasia (SPEM; Fig. 2
a, b; Supplementary Fig. 3 b, c), and pancreatic acinar cells also showed the decreased cell
volume with increased lumens in the pattern known as Acinar to Ductal Metaplasia (ADM; Fig.
2 e, f; Supplementary Fig. 3 d, e). Previously shown that IFRD1 is also induced precancerous
and cancerous epithelial lesions in the human luminal gastrointestinal tract 6; we show here that
it also is strongly expressed in regions of acinar-ductal metaplasia in a patient with pancreatic
ductal adenocarcinoma (Fig. 2g).
Mice lacking IFRD1 had aberrant paligenosis. In stomach, the base of the gastric unit,
where paligenosis occurs, showed marked cell loss (Fig. 2 a, b), and pancreas also showed
regions of epithelial loss with increased stroma and tissue edema (Fig. 2e). Proliferation was
significantly decreased in paligenotic Ifrd1−/− cells (Fig. 2). In stomach, decreased proliferation
was confined to the base where paligenosis occurs, whereas cells higher in the gastric unit in the
constitutively proliferative stem cell zone (the isthmus) were largely unaffected either before or
after HD-TAM (Fig. 2 c, d). In pancreas, proliferating paligenotic acinar cells were greatly
reduced, while proliferating cells in the stroma were largely unaffected (Fig. 2 h, i). To further
test the role of IFRD1 in paligenotic proliferation, we performed partial hepatectomies, which we
and others have shown involve paligenotic recruitment of hepatocytes back to a proliferative
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state 1. Mitotic activity in Ifrd1−/− livers following partial hepatectomy was also compromised
(Supplementary Fig. 2 g, h)
Re-entry into the cell cycle is the third stage of paligenosis, so the decreased proliferation
in the absence of IFRD1 could be due to upstream failure of cells to progress through stages 1 or
2. In both the pancreas and stomach, the massive upregulation of LAMP1+ vesicles
characteristic of the autodegradation phase occurred in Ifrd1−/− mice (Supplementary Fig. 3 b, d),
so there was no obvious defect in the autodegradative stage 1. Likewise, the characteristic reexpression of the mucous neck cell pattern in paligenotic chief cells of the stomach
(Supplementary Fig. 3c) and paligenotic expression of nuclear YAP1 (Supplementary Fig. 3e)
and SOX9 (unpublished observations) in paligenotic acinar cells were observed as expected in
Ifrd1−/− mice. Thus, paligenosis stage 2 was not markedly affected by loss of IFRD1.
Loss of IFRD1 causes increased activation of p53 and decreased expression of mTORC1associated and cell-cycle-related transcripts
We next explored the mechanism IFRD1 uses to regulate paligenosis. Our analysis of
IFRD1 structure revealed a protein without catalytic domains that is remarkably conserved in
both the recurring α-helices in armadillo folds with scant variation in overall length across all
eukaryotes. Overall, the structure and conservation suggest it acts as a scaffold that interacts with
multiple other proteins throughout its entire length. Accordingly, previous reports have arrived at
neither consistent function nor even cellular localization of IFRD1 with some studies showing
interactions with nuclear histone deacetylases to govern chromatin modification 17-19, others
suggesting that it likely is cytosolic and interacts with ribosomes 20, and still others indicating
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interaction with multiple signaling pathways including IL6/JAK/STAT/NF-κB, MAP Kinases,
Hippo, Wnt, and mTOR

2 21 22 23 24

.

Thus, IFRD1 is likely to function as a central hub with numerous potential binding
partners in cytosol and nucleus. To begin to identify the most salient mechanisms, we performed
global gene expression profiling of whole pancreas of Ifrd1−/− and control mice ± cerulein at the
time point when the greatest number of cells are in stage 3 of paligenosis, when the IFRD1
phenotype manifests. Gene Set Enrichment Analysis (GSEA) using publicly available cell cycle
data sets (Molecular Signatures Database, Broad Institute25 ) confirmed dramatic, statistically
significant de-enrichment for cell cycle transcripts in Ifrd1−/− mice (Fig. 3a), consistent with the
histological data. Furthermore, when we analyzed the Broad Institute Hallmark collection of
GSEA datasets (a compendium of gene sets designed for unbiased screens) for any gene sets that
significantly distinguished cerulein-injured Ifrd1−/− pancreases from control, we noted marked
de-enrichment again of additional cell cycle-related gene sets (G2M Checkpoint, Mitotic
Spindle, myc Targets). In addition, in the absence of IFRD1, there was also de-enrichment for
gene sets associated with p53, DNA repair, and mTORC1 (Fig. 3b).
The Hallmark p53 gene set comprises p53- upregulated and downregulated genes, as well
as genes associated with or modifying p53. To determine which genes were principally
responsible for the differential p53 gene expression between Ifrd1−/− mice and controls, we
examined the most increased genes in wildtype (i.e. the ones primarily responsible for p53associated gene enrichment in wildtype mice). The top 10 most-enriched transcripts in control
vs. Ifrd1−/− mice were all either promoters of cell cycle progression (CCND1, CCND2, CCNG1,
GTSE1, CDK1), anti-apoptotic (SESN2, SESN3, MDM2) or miscellaneous (SERPINB5,
THBS1). Furthermore, Western blots for p53 in untreated and paligenotic stomachs and
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pancreases showed that p53 expression was dramatically increased in Ifrd1−/− mice (Fig. 3c).
The p53 activation in Ifrd1−/− mice likely explains why cell-cycle and anti-apoptotic genes –
whose expression is inhibited by p53 – were upregulated in control mice vs. Ifrd1−/− mice,
accounting for both the GSEA pattern and suggesting a p53-dependent mechanism to reduce
proliferation in the absence of IFRD1.
Decreased mTORC1-associated transcripts in Ifrd1−/− pancreas during paligenosis
suggested an additional possible mechanism for cell cycle blockade. Our previous studies
demonstrated that mature acinar and chief cells maintain high levels of digestive enzyme
translation and secretion via activated mTORC1 at homeostasis. However, mTORC1 is
quenched during stages 1 and 2 of paligenosis then reactivated in stage 3 where it is required to
drive cells from G1 to S-phase of the cell cycle 1. Hence, given the defective proliferation in
Ifrd1−/− mice, we would expect that the re-induction of mTORC1 function might be
compromised.
IFRD1 is required for normal mTORC1 reactivation and cell survival in stage 3 of
paligenosis
To assay mTORC1 activity in individual paligenotic cells we used phosphorylated S6
(PS6) ribosomal protein, whose kinase is a target of mTORC1. We previously showed by
multiple methods that pS6 is a faithful proxy for mTORC1 activity in individual cells 1. At
homeostasis, in mature chief and acinar cells, pS6 was not affected by loss of IFRD1 (Fig. 4 a,
d). However, at the time points when control mice show maximal census of stage 3 paligenotic
cells, pS6 expression was markedly aberrant. In stomach, all control paligenotic cells expressed
abundant pS6 as expected, but in Ifrd1−/− mice, even in regions where the paligenotic portions of
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glands had not been lost, pS6+ cells were both rarer and often showed less intense expression
(Fig. 4a). In pancreas, scattered cells showed high pS6 expression (Figure 4d), but many others
showed low to undetectable expression. To confirm aberrant mTORC1 activity following loss of
IFRD1, we used HALO Image Analysis Software to quantify pS6 distribution. In control mice
only 10% of acinar cells were negative for pS6, while nearly half of Ifrd1−/− acinar cells were
negative at d5 of cerulein. (Fig. 4e and Supplementary Fig. 4).
Thus, the loss of proliferation in stage 3 of Ifrd1−/− mice correlated with decreased
reactivation of mTORC1 and increased p53 activation. As mTORC1 and p53 are both associated
with cell survival as well as proliferation, we next investigated the effects of loss of IFRD1 on
cell death. Previously, we have shown that there is minimal apoptosis in paligenosis induced by
HD-TAM or cerulein, as measured either by loss of tissue in regions of paligenosis or activation
of cleaved caspase 3 1. We also showed that aberrant paligenosis (e.g. by inhibiting stage 1
progression) can lead to increased apoptosis following injury. We confirmed low-level cleaved
caspase 3 in control paligenotic stomach and pancreas; in contrast, Ifrd1−/− mice showed marked,
significantly increased apoptosis (Fig. 4 b, c, f, g). Note that by d3 after HD-TAM, many of the
paligenotic gland bases in stomach had entirely atrophied in Ifrd1−/− mice as described above, so
the increased cleaved caspase 3 positive cells are in regions that have not yet been lost as
depicted in Fig. 4b.
Ifrd1−/− cells fail to re-enter the cell cycle due to inappropriate activation of p53
Failure of Ifrd1−/− cells to reactivate mTORC1 could be responsible for the block in
proliferation. However, our previous work did not indicate that loss of mTORC1 caused marked
increase in cell death, so the fact that loss of IFRD1 caused increased death as well as decreased
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proliferation would not necessarily be explained by simple failure to reactivate mTORC1.
Furthermore, even without IFRD1, there was a substantial fraction of strongly pS6+ cells,
especially in pancreas, indicating that some paligenotic cells could activate pS6 as robustly as
wildtype cells. Another possibility is that the overall decreased fraction of pS6+ cells was
because mTORC1 activation in the absence of IFRD1 leads to apoptosis rather than mitosis, thus
removing many pS6+ cells from the tissue.
Aberrant p53 activation can lead to cell cycle arrest or delay both by blocking mTORC1
activation and by blocking ribosome biogenesis using transcriptional and translational
mechanisms 26 27 28.Thus loss of IFRD1 could activate p53 to block mTORC1 and therefore entry
into S-phase. We generated Ifrd1−/−;Trp53−/− mice and tested effects on paligenosis in stomach
and in pancreas. In both stomach and pancreas, loss of p53 substantially and significantly
rescued the proliferation block in Ifrd1−/− mice (Fig. 5 a - d, f - h). Thus, in the absence of p53,
IFRD1 no longer was required for cells to progress through the cell cycle. As mTORC1 is
required for S-phase, the results indicated that IFRD1 was not required for mTORC1 activation,
and, accordingly, Supplementary Fig. 5 shows that S6 activation was similar to wildtype when
both p53 and IFRD1 were deleted. In stomach, loss of both p53 and IFRD1 also significantly
decreased the number of dying cells seen in paligenosis when only Ifrd1 was deleted (Fig. 5e).
However, in pancreas, loss of p53 did not change the Ifrd1−/− cell death phenotype, indicating
p53 is required for Ifrd1−/− gastric paligenotic death but the pancreas may have additional, p53independent factors that can still cause apoptosis (Fig. 5i).
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mTORC1 suppresses p53 and is required for cell cycle entry and for cell death in the
absence of IFRD1
Overall, the results indicate that IFRD1 suppresses p53 in Stage 3 of paligenosis such that
loss of IFRD1 activates p53 to block the cell cycle and, in the stomach, to cause death. IFRD1
appears to interact with mTORC1 only via p53, as pS6 was delayed but not blocked in Ifrd1−/−
mice and, once p53 was also deleted (i.e. in Ifrd1−/−;Trp53−/− mice), mTORC1 activation and
proliferation were similar to wildtype (Supplementary Fig. 5). We next sought to further
determine the relationship of mTORC1 to p53 and IFRD1. We treated control and Ifrd1−/− mice
with the mTORC1 inhibitor rapamycin during paligenotic injury, using the protocol previously
detailed 1. mTORC1 blockade did not rescue the proliferation block in stomachs of Ifrd1−/− mice,
which was expected because entry into S-phase requires mTORC1 (Fig. 6 b, c). However,
rapamycin did inhibit cell death, which was quantified in the stomach at maximal paligenosis
(Fig. 6 a, b, d). mTORC1 suppresses p53 activation, and western blot showed that p53 was
activated in the absence of mTORC1 (Supplementary Fig. 6). Thus, p53 activation alone does
not cause death; death also requires mTORC1 activation.
In the pancreas, we can do more chronic injury to determine how loss of IFRD1
±mTORC1 affects overall tissue regeneration, whereas HD-TAM causes mouse death if it is not
discontinued after maximal paligenosis. Two-week cerulein in Ifrd1−/− mice caused near total
destruction of acinar cells; thus, IFRD1 regulation of paligenosis is absolutely required for tissue
repair/survival in this organ (Figure 6E). Rapamycin largely rescued the Ifrd1−/− cell death,
though paligenotic proliferation was still impaired relative to wildtype (Figure 6F).
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Chapter 4.4 CONCLUSIONS
Here, we identify IFRD1 as the first evolutionarily conserved gene whose principal
function seems to be to govern paligenosis. IFRD1 is remarkably conserved in structure and
length from yeast to humans. Its expression is critical for injury response but mostly dispensable
for homeostasis. It is critical for cell cycle re-entry and survival in stage 3 of paligenosis.
Epistasis experiments indicate it principally works to suppress the p53-mediated suppression of
mTORC1 (Fig. 7). The suppression of p53 is critical specifically in an injury-induced, mTORC1dependent cell cycle re-entry context because a) Ifrd1−/− mice have constitutive p53 activation
but have no proliferative or developmental phenotype in pancreas or stomach or liver in the
absence of injury and b) when mTORC1 is inactive Ifrd1−/− mice and wildtype mice show
similar phenotypes.
To our knowledge, this is the first report to show IFRD1-mediated repression of p53. The
central location of IFRD1 as a regulator of p53 in the specific paligenotic context of increased
mTORC1 during cell cycle reentry of mature cells makes teleological sense. Multicellular
organisms have the advantage of being able to dedicate the vast majority of cells to specific
functions; however, paligenosis also allows those cells to act as a large reservoir of potential
stem cells to repair damage of organs throughout life. In the pancreas, as shown here, the
inability to undergo paligenosis, in the absence of tissue stem cells, can be catastrophic (Fig. 6e).
There are risks, however, in allowing long-lived cells to cycle between replicative and
differentiated states, because mutations could potentially accumulate over time increasing cancer
risk with each paligenotic event 29,30. A robust licensing mechanism that is dedicated to
regulating paligenotic cell cycle entry – and would not affect constitutive cycling of homeostatic
tissue stem cells -- would make sense. That is, in fact, why it has been speculated p53 evolved in
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multicellular organisms and not yeast 31: Multicellular organisms can afford to waste cells via
apoptosis to avoid cancer risk. Our previous results showing increased IFRD1 predicts poor
outcome in colon cancer is consistent with the potential for tumor cells to exploit IFRD1
suppression of p53 to subvert cell cycle delay and apoptosis 6.
Here, we outline a central hub that performs the key, conserved licensing steps allowing
mature cells to re-enter the cell cycle, describing critical roles for mTORC1, p53, and a gene
whose function seems to have evolved largely to dictate paligenosis. There is likely a dedicated
cohort of other genes that govern this cellular program that acts on injured mature cells that reach
the decision crux between apoptosis and mitosis. Because paligenosis is at the heart of both
regeneration and tumorigenesis, delineating the underlying genes can lead to better
understanding that might spur new therapeutic approaches.
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Chapter 4.5 FIGURES

FIGURE 4.1
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Fig. 1 IFRD1 is highly conserved and is upregulated following regeneration-inducing
injury in multiple tissues and species
a. Venn diagram depicting coinciding genes up-regulated in each model. Green = high-dose
tamoxifen-induced gastric metaplasia (Spasmolytic Polypeptide Expressing Metaplasia),
blue = cerulein injury-induced pancreatic metaplasia (Acinar-Ductal Metaplasia), red =
partial liver resection, yellow = glycerol-induced acute kidney injury.
b. Analysis showing the relative gene expression of coinciding genes in injury models.
c. Multiple sequence alignment of Ifrd1 across evolutionary spectrum. Secondary structural
prediction from H. sapiens sequence.
d. Image of the localization of GFP driven by Ifrd1 promoter in Drosophila melanogaster
intestine at baseline and under H2O2 stress. Scale bar, 100µM
e. Quantitative analysis of pHH3+ cells in Drosophila intestine sections. ΔdIFRD1 #1 and
#2 are hypomorphic for difrd1.Statistical information: N.S. = not statistically significant,
**P < 0.01; ***P < 0.001 by t-test with unequal variance; data represented as mean ± SD
from at least 3 independent experiments.
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FIGURE 4.2
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Fig. 2 IFRD1 is required for stage 3 of paligenosis
a. Histological analysis of wildtype and Ifrd1−/− mice after day 3 high-dose tamoxifen
(hdtam d3) treatment. Scale bar, 50µM.
b. High magnification histological analysis of zymogenic chief cells from Ifrd1−/− vehicle,
wildtype hdtam d3 and Ifrd1−/− hdtam d3. Black outline = normal chief cell histology,
yellow outline = normal histological metaplasia (SPEM), yellow arrows = representative
metaplastic changes in chief cells, red outline = area of zymogenic chief cell dropout.
c. Immunohistological analysis of BrdU staining in gastric units from mice vehicle and
hdtam d3 treated wildtype and Ifrd1−/− mice. Dotted line = representative chief cell zone
(100µM perpendicular to muscularis mucosa). Scale bar, 50µM.
d. Quantitative analysis of BrdU+ cells the chief cell zone of vehicle and hdtam d3 treated
wildtype and Ifrd1−/− mice. Statistical information: N.S. = not statistically significant,
**P < 0.01; ***P < 0.001 by t-test with unequal variance; data represented as mean ± SD
from at least 3 independent experiments.
e. Histological analysis of wildtype and Ifrd1−/− mice 5 days post cerulein treatment. Scale
bar, 50µM.
f. High magnification histological analysis pancreatic acinar cells of vehicle treated Ifrd1−/−
mice, cerulein treated wildtype mice and cerulein treated Ifrd1−/− mice.
g. Immunohistological staining of IFRD1 human pancreas tissue. Scale bar, 50µM.
h. Immunoflourescent imaging of BrdU incorporation 5 days post-cerulein treatment in
wildtype and Ifrd1−/− mice. Yellow arrow = AMYLASE/BRDU co-positive cells. Scale
bar, 50µM.
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i. Quantification of BrdU+ cell number per 20X field at 5 days post cerulein. Statistical
information: N.S. = not statistically significant, **P < 0.01; ***P < 0.001 by t-test with
unequal variance; data represented as mean ± SD from at least 3 independent
experiments.
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FIGURE 4.3
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Fig. 3 Loss of IFRD1 causes increased activation of p53 and decreased expression of
mTORC1-associated and cell-cycle-related transcripts
a. Global gene expression profiling of pancreas tissue Ifrd1−/− and control mice ±cerulein at
5 days post-cerulein using Gene Set Enrichment Analysis (GSEA) utilizing publicly
available cell cycle data sets.
b. Unbiased screen of Broad Institute Hallmark data sets using GSEA to uncover gene sets
that significantly distinguish cerulein-injured Ifrd1−/− pancreases from control.
c. Western blot for p53 untreated and paligenotic stomachs and pancreases.
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FIGURE 4.4
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Fig. 4 IFRD1 is required for normal mTORC1 reactivation and cell survival in stage 3 of
paligenosis
a. Immunoflourescent analysis of phosphorylated-S6 (pS6) staining in wildtype and Ifrd1−/−
mice following vehicle or hdtam d3 treatment. Scale bar, 20µM.
b. Immunohistological analysis of Cleaved-Caspase 3 (CC3) staining in wildtype and
Ifrd1−/− mice following hdtam d3 treatment. Scale bar, 50µM.

c. Quantification of CC3+ cells per 20X field in wildtype and Ifrd1−/− mice following vehicle
or hdtam d3 treatment. Statistical information: N.S. = not statistically significant, **P <
0.01; ***P < 0.001 by t-test with unequal variance; data represented as mean ± SD from
at least 3 independent experiments.
d. Immunoflourescent analysis of pS6 staining in wildtype and Ifrd1−/− mice 5 days
following vehicle or cerulein treatment. Scale bar, 50µM.
e. Quantitative analysis using the HALO imaging software of areas of the pancreas
demonstrating ADM that are lacking pS6 expression per 20X field. N.S. = not
statistically significant, **P < 0.01; ***P < 0.001 by t-test with unequal variance; data
represented as mean ± SD from 5 images from 4 independent experiments.
f. Immunohistological analysis of CC3 staining in wildtype and Ifrd1−/− mice 5 days
following cerulein treatment. Scale bar, 50µM.
g. Quantification of CC3+ cells per 20X field in wildtype and Ifrd1−/− mice 5 days following
cerulein treatment. Statistical information: N.S. = not statistically significant, **P < 0.01;
***P < 0.001 by t-test with unequal variance; data represented as mean ± SD from at
least 3 independent experiments.
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FIGURE 4.5
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Fig. 5 Ifrd1–/– cells fail to re-enter the cell cycle due to inappropriate activation of p53
a. Histological analysis of wildtype mice treated with hdtam d3. Smaller panels show
representative and high magnification immunohistological imaging of pHH3 and CC3
staining. Histology scale bar, 50µM. Immunohistological scale bar, 20µM.
b. Histological analysis of Ifrd1–/– mice treated with hdtam d3. Smaller panels show
representative and high magnification immunohistological imaging of pHH3 and CC3
staining. Histology scale bar, 50µM. Immunohistological scale bar, 20µM.
c. Histological analysis of Ifrd1–/–;p53–/– mice treated with hdtam d3. Smaller panels show
representative and high magnification immunohistological imaging of pHH3 and CC3
staining. Histology scale bar, 50µM. Immunohistological scale bar, 20µM.
d. Quantitative analysis of pHH3+ cells in wild type, Ifrd1–/– and Ifrd1–/–;p53–/– mice treated
with hdtam d3. Statistical information: N.S. = not statistically significant, **P < 0.01;
***P < 0.001 by t-test with unequal variance; data represented as mean ± SD from at
least 3 independent experiments.
e. Quantitative analysis of CC3+ cells in wild type, Ifrd1–/– and Ifrd1–/–;p53–/– mice treated
with hdtam d3. Statistical information: N.S. = not statistically significant, **P < 0.01;
***P < 0.001 by t-test with unequal variance; data represented as mean ± SD from at
least 3 independent experiments.
f. Histological analysis of wildtype, Ifrd1–/–and Ifrd1–/–;p53–/– mice 5 days following
treatment with cerulein. Scale bar, 50µM.
g. Immunohistological analysis of pHH3+ and CC3+ wildtype, Ifrd1–/–and Ifrd1–/–;p53–/–
mice 5 days following treatment with cerulein. Scale bar, 20µM.
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h. Quantitative analysis of pHH3+ cells in wild type, Ifrd1–/– and Ifrd1–/–;p53–/– mice 5 days
following treatment with cerulein. Statistical information: N.S. = not statistically
significant, **P < 0.01; ***P < 0.001 by t-test with unequal variance; data represented as
mean ± SD from at least 3 independent experiments.
i. Quantitative analysis of CC3+ cells in wild type, Ifrd1–/– and Ifrd1–/–;p53–/– mice 5 days
following treatment with cerulein. Statistical information: N.S. = not statistically
significant, **P < 0.01; ***P < 0.001 by t-test with unequal variance; data represented as
mean ± SD from at least 3 independent experiments.
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FIGURE 4.6
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Fig. 6 mTORC1 suppresses p53 and is required for cell cycle entry and for cell death in the
absence of IFRD1
a. Histological analysis of hdtam d3 treated wildtype, Ifrd1–/– and Ifrd1–/– + rapamycin mice.
Scale bar, 50µM.
b. Immunohistological analysis pHH3+ and CC3+ cells of hdtam d3 treated wildtype, Ifrd1–/–
and Ifrd1–/– + rapamycin mice. Scale bar, 20µM.
c. Quantitative analysis of pHH3+ cells in wild type, Ifrd1–/– and Ifrd1–/– + rapamycin mice
treated with hdtam d3. Statistical information: N.S. = not statistically significant, **P <
0.01; ***P < 0.001 by t-test with unequal variance; data represented as mean ± SD from
at least 3 independent experiments.
d. Quantitative analysis of CC3+ cells in wild type, Ifrd1–/– and Ifrd1–/– + rapamycin mice
treated with hdtam d3. Statistical information: N.S. = not statistically significant, **P <
0.01; ***P < 0.001 by t-test with unequal variance; data represented as mean ± SD from
at least 3 independent experiments.
e. Histological analysis of 2 weeks cerulein treated wildtype, Ifrd1–/– and Ifrd1–/– +
rapamycin mice. Scale bars, 200µM (top), 50µM (bottom).
f. Immunohistological analysis pHH3+ cells of 2 weeks cerulein treated wildtype, Ifrd1–/–
and Ifrd1–/– + rapamycin mice. Scale bar, 20µM.
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FIGURE 4.7
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SUPPLEMENTARY FIGURE S4.1
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Supplementary Fig. 1 IFRD1 structure exhibits broad evolutionary conservation
a. Phylogenetic tree generated from multisequence analysis of IFRD1 orthologs across
numerous classes from three phyla using Clustal Omega webserver.
b. Multisequence alignment of IFRD1 (H. sapiens) to IFRD2 (O. cuniculus). Secondary
structure for IFRD1 was computed using JPred4 webserver and secondary structure for
IFRD2 was computed from the atomic coordinates of the recently reported cryoEM
structure of IFRD2 bound to the ribosome (PDB 6MTC).
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SUPPLEMENTARY FIGURE S4.2
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Supplementary Fig. 2 IFRD1 function is cell-autonomous and is required
proliferation/regeneration in multiple systems
a. Low (4X) magnification images of organoids derived from wild type and Ifrd1–/– mice.
b. Quantification of enteroid initiation efficiency of wild type and Ifrd1–/– mice. Statistical
information: N.S. = not statistically significant, **P < 0.01; ***P < 0.001 by t-test with
unequal variance; data represented as mean ± SD from at least 3 independent
experiments.
c. High power image of a single representative organoid from wild type and Ifrd1–/– mice.
Scale bar, 300µM.
d. Quantification of enteroid size on day 6 of wild type and Ifrd1–/– mice. Statistical
information: N.S. = not statistically significant, **P < 0.01; ***P < 0.001 by t-test with
unequal variance; data represented as mean ± SD from at least 3 independent
experiments.
e. Representative images of axon regeneration following axotomy ex vivo of control and
shRNA knockdown of Ifrd1 (shIfrd1). Scale bar, 500µM.
f. Quantification of axon regeneration following axotomy. Statistical information: N.S. =
not statistically significant, **P < 0.01; ***P < 0.001 by t-test with unequal variance;
data represented as mean ± SD from 5 independent experiments.
g. Histological analysis partially resected livers from wild type and Ifrd1–/– mice. Scale bar,
50µM.
h. Quantification of pHH3+ cells per 20X field following partial hepatectomy in wild type
and Ifrd1–/– mice.
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SUPPLEMENTARY FIGURE S4.3
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Supplementary Fig. 3 In the absence of IFRD1, mice do not have substantial defects in
development, homeostasis or early stages of paligenosis
a. Schematic image of the 3 stages of paligenosis.
b. Immunoflourescent analysis of activation of lysosomal machinery (paligenosis Stage 1)
in chief cells of wild type and Ifrd1–/– mice treated with d1 hdtam. DAPI: 4′,6-diamidino2-phenylindole (nucleus). LAMP1: lysosomal associated membrane protein (lysosomes).
PGC: Pepsinogen C (protease secreted by gastric chief cell). Scale bar, 20µM.
c. Immunoflourescent analysis of the metaplastic gene expression (paligenosis Stage 2) in
chief cells of wild type and Ifrd1–/– mice treated with d3 hdtam. GSII: Nacetylglucosamine-binding lectins (neck cell). PGC: Pepsinogen C (protease secreted by
gastric chief cell) Scale bar, 50µM.
d. Immunoflourescent analysis of activation of lysosomal machinery (paligenosis Stage 1)
in acinar cells of wild type and Ifrd1–/– mice 1 day following treatment with cerulein.
DAPI: nucleus. LAMP1: lysosomes. CPA1: Carboxypeptidase A1 (digestive enzyme
secreted by pancreatic acinar cells). Scale bar, 50µM.
e. Immunoflourescent analysis of the metaplastic gene expression (paligenosis Stage 2) in
acinar cells of wild type and Ifrd1–/– mice 5 days following treatment with cerulein.
YAP1: Yes-associated protein 1 (baseline- duct cell; cerulein- acinar and duct cells).
Scale bar, 50µM.
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SUPPLEMENTARY FIGURE S4.4

Supplementary Fig. 4 Representative image of HALO imaging software
a. Representative image of the identification of positive (yellow, orange, and red) and
negative (no color) cells using the HALO imaging software in wild type and Ifrd1–/– mice
5 days following treatment with cerulein.
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SUPPLEMENTARY FIGURE S4.5
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Supplementary Fig. 5 Loss of p53 rescues the mTORC1 defect in Ifrd1−/− mice
a. Immunoflourescent analysis of PS6 staining in in wild type, Ifrd1–/– and Ifrd1–/–;p53–/–
mice treated with hdtam d3. Scale bar, 50µM.
b. Immunoflourescent analysis of PS6 staining in in wild type, Ifrd1–/– and Ifrd1–/–;p53–/–
mice 5 days following treatment with cerulein. Scale bar, 50µM.
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SUPPLEMENTARY FIGURE S4.6

Supplementary Fig. 6 mTORC1 inhibition causes the stabilization of p53
a. Western blot for p53 and Ps6 in untreated and rapamycin treated stomachs.
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Chapter 4.6 METHODS
Bioinformatics, microarray and in silico screening
GeneChips were analyzed with Partek Genomic Suite 6.6 (Partek, Inc.) analysis software
using default settings (Lo et al. 2017). Gene sets include Tamoxifen (12 hour; generated by Jason
Mills lab), Pancreas (6 hour; GDS1731), Partial Hepatectomy (2 hour, GDS2577), Acute Kidney
Injury (24h, GDS4864), Ventilator-Induced Lung Injury (6 hour, GDS81240), and Candoxin
Glia Injury (24 hour, GDS1414). Thresholds were set at 1.5-fold gene enrichment for all gene
sets.
GSEA (Subramanian et al., 2005), was done using default 3.0 settings. GMX files were
made using microarray data generated de novo from WT and Ifrd1−/− pancreas tissue treated with
cerulein (GSE121925, available May 1, 2019). RNA was isolated using the RNEasy Micro Kit
(Qiagen) following the manufacturers’ instructions. Mouse Gene 2.0 ST Array (Affymetrix) was
used to the analyze gene expression. Multisequence alignments and phylogenetic analysis are
presented as uncurated results from Clustal Omega Webserver (Sievers Mol System Biol,
http://msb.embopress.org/content/7/1/539). Secondary structure prediction was computed with
the JPred4 webserver (Drozdetskiy NAR, 2015) using the sequence of human IFRD1.
Animal studies and reagents
All experiments using animals followed protocols were approved by the Washington
University School of Medicine Animal Studies Committee. WT C57BL/6 mice were purchased
from Jackson Laboratories (Bar Harbor, ME). Ifrd1−/− mice, previously described (Vadivelu et
al. 2004), were a kind gift from Dr. Lukas Huber and Dr. Deborah Rubin. Tamoxifen (5 mg/20 g
body weight; Toronto Research Chemicals) was injected intraperitoneally (IP) daily for 2–3 days
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to induce maximal gastric injury (Huh et al, 2012; Saenz et al, 2016). Tamoxifen was prepared
by first dispersing in 100% ethanol by sonication and then emulsifying in sunflower oil (Sigma‐
Aldrich) 9:1 (oil:ethanol). Pancreatitis was induced by 6 hourly IP injections of 50 µg/kg (in
0.9% saline) cerulein (Sigma‐Aldrich) given every other day for up to 2 weeks. Mice were
sacrificed 24h after the final cerulein injection. Rapamycin (60 µg/20 g body weight; LC
Laboratories) was injected IP in 0.25% Tween‐20, 0.25% polyethylene glycol in PBS for 3–
7 days prior to starting and throughout injury time course. Mice were given an IP injection
containing 5‐bromo‐2′‐deoxyuridine (BrdU; 120 mg/kg) and 5‐fluoro‐2′‐deoxyuridine
(12 mg/kg) in sterile water 90 min before sacrifice for all BrdU labeling experiments.
Drosophila studies
Mammalian ifrd1 homolog is CG31694 (difrd1 here). Fly stocks were obtained from the
Bloomington Drosophila stock center. yw; P(EPgy2)EY11632 (BL#20811; designated as difrd1
#1), yw; P(PTT-GA)CA07748 (BL#52520; designated as difrd1 #2 or ifrd1-GFP). w1118 or
Canton-S are used as wild types. All flies were cultured on yeast-molasses based on food at the
room temperature.
Flies were anesthetized by CO2 gas and were stored on ice until dissection. Midguts were
dissected in fly saline (182mM KCl, 46mM NaCl, 10mM Tris Base, 3mM CaCl2, pH adjusted to
7.2 with 1N HCl) and transferred to fixation solution (4% formaldehyde, 7% picric acid in 1X
PBS) for 1h at room temperature while shaking. All samples were washed by Washing buffer
(1X PBT: 1x PBS and 0.3% Triton X-100) several times for 1h and blocked in the pre-incubation
buffer (1X PBT containing 1% BSA and 1% normal goat serum, 0.01% Sodium Azide). Primary
antibodies were diluted in the same buffer. Midguts were incubated in antisera overnight at 4°C
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with shaking. After intensive washing, midguts were incubated with secondary antibodies
(Alexa-488/ -594/ -647 conjugated IgG antibodies, 1:1000) for 1h at room temperature. After
washing twice for 15 minutes, midguts were stained with 1 μg/mL DAPI in 1x PBT for 15min,
followed twice more washing and mounted in Vectashield medium (Vector Laboratories).
For heat shock stress, female flies were incubated at 37oC for 90 minutes and recovered
for more than 2 days at room temperature. For oxidative stress, female flies were raised in vials
containing 1 mL of 2% sucrose solution with or without 3% hydrogen peroxide for overnight.
Fly guts were dissected in saline and fixed (7% picric acid/4% paraformaldehyde, 1X PBS) for
60 min. The immunostaining was performed as previously described (Park et al., 2008). Primary
antibodies used for immunocytochemistry included rabbit anti-PH3 (Cell Signaling, 1:1000) and
mouse anti-GFP (DHSB, 1:200). Conjugated secondary antibodies were Alexa488 or Alexa594
(Molecular Probes).
Organoid culture
Enteroid cultures were established from crypts isolated from WT or Ifrd1−/− proximal
jejunum. Crypts were plated in Matrigel and grown into enteroids in media containing EGF, Rspondin, Wnt3a, noggin and Y27632 (Sata et al. 2009, Fuller et al. 2012). Enteroids were then
re-passaged twice at 7 day intervals to measure replating efficiency, and harvested for RNA on
day 21. Enteroid numbers and area were quantified from images of each well obtained on days 6,
13 and 20 using Cytation 3 Cell Imaging. The efficiency of enteroid establishment from crypts
was calculated as the number of enteroids on day 6 normalized to the number of crypts plated.
Enteroid area was measured at each time point using NIH ImageJ.
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Axon Regeneration
Embryonic DRG neurons were cultured as previously described (Cho and Cavalli, 2012).
Briefly, e13.5 DRG neurons were dissected from CD-1 mice, trypsinized (.05%) for 25 minutes,
and triturated 60x to dissociate the cells. Neurons were resuspended in neuronal media consisting
of Neurobasal, 1x B27, 1x Glutamax, FDU, and pen/strep, and were plated in spots of 10,000
neurons on plates coated with poly-d-lysine and laminin. Lentivirus containing FCIV-Bclxl was
added at DIV 2 and shIFRD1 at DIV4. At DIV 9, spots were axotomized with an 8mm long
microtome blade and fixed 48 hours after injury. Spots were immunostained for SCG10 and
regenerative growth was measured from the blade mark to the axon tips. The experiments were
completed in technical triplicate with 8 biological replicates.
Imaging and tissue analysis
Mouse tissues were immediately excised and flushed with phosphate‐buffered saline and
fixed overnight in 4% paraformaldehyde in PBS. Tissues were washed, embedded in 3% agar,
and then underwent routine paraffin processing. Sections prepared for immunofluorescence or
immunohistochemistry underwent standard deparaffinization and rehydration protocols, were
blocked in 5% normal serum, and left overnight with primary antibodies. Sections were washed
in phosphate‐buffered saline and incubated for 1 h with secondary antibodies and then washed
prior to mounting. For antibodies used in this study, see (Supplementary Table _).
Immunofluorescence images were taken on a Zeiss Apotome or LSM710 confocal (Zeiss).
Bright field images were taken on a Nanozoomer (Hamamatsu) whole slide scanner or DP70
microscope (Olympus). To account for frequent gland loss in the base of Ifrd1−/− mice, 10
random, 20X fields were chosen in three Ifrd1−/− and three control animals. The 10 fields were
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further subdivided into two rectangular regions: a basal one 100 μm perpendicular and 450 μm
parallel to the muscularis mucosa and a region of the same size immediately adjacent and
encompassing the neck of the gastric unit. All BrdU+ or pHH3 cells were scored and the
proportion in each zone calculated. Quantification of proliferation in the pancreas was done by
counting 10 randomly sampled whole 20X fields per condition. HALO image analysis platform
(Indica Labs) to quantify intensity of fluorescent staining. We selected 5 pancreas images per
four Ifrd1−/− and four control animals that exhibited pathological ADM. Exposure times were
kept constant across all samples and images were analyzed based on the intensity of fluorescence
per cell. The staining threshold was set based on control tissue for positive staining. Statistical
analysis with both antibodies was done using ANOVA with a post hoc Dunnett's test.
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Chapter 5: Conclusions and Future
Directions
Chapter 5.1: Summary
In summary, the work described in this dissertation details significant advancements in
the molecular basis of disease and injury in gastrointestinal tissues. We have described the
process, paligenosis, by which mature cells can alter their differentiation state and become
proliferative, in response to injury. We detailed the specific steps that occur during this process,
and we have begun to highlight some of the major pathways involved. We began by
investigating cellular dynamics that play an important role in whole tissue function in gastric
chief cells and pancreatic acinar cells. We uncover the importance of mTORC1 as a central
regulator of this process in both the stomach and pancreas. We investigated this process in
numerous tissues and proposed that paligenosis is a conserved a shared mechanism. My work in
the Mills lab has also specifically helped build upon the idea of paligenosis in two important
ways: 1) establishment of the cerulein-based pancreatitis model that has enabled us to thoroughly
characterize paligenosis as a shared process and 2) the identification of Ifrd1 as a gene that is
commonly upregulated in cells that undergo paligenosis. We characterized IFRD1 in numerous
tissues, across several species and we now know that it is critical for the proliferation of cells
undergoing paligenosis in diverse contexts. We discovered that IFRD! is highly evolutionarily
conserved, and this work has led to a burgeoning project in the lab focusing on paligenosis in
Drosophila. My initial bioinformatic screen helped support projects in the lab characterizing
paligenosis genes like Ddit4 and Atf3. My work on paligenosis and Ifrd1 uncovered new and
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intersected with known hubs of cellular biology that are conserved to yeast including mTOR,
P53, nucleolar stress and MAPK signaling1-4. Ultimately, our research aims to influence the
understanding of human disease and paligenosis sheds light on the way that secretory cells can
fuel GI adenocarcinomas. To that end, we analyzed IFRD1 in human colorectal cancers and
observe a significant correlation between IFRD1 expression and patient survival.
Chapter 5.2: Future Directions
Crafting a dissertation project around IFRD1 has been a mixed blessing. The scant
literature on IFRD1 in relation to our model systems has made it so that we, along with Dr.
Deborah Rubin, have been able to help set a foundational understanding of this gene. However,
my dissertation research concludes with many unanswered questions that I will describe
throughout the rest of this chapter.
IFRD1 in ex vivo culture
We have previously experienced mixed results when attempting to generate gastroids
from Ifrd1–/– mice. The most interesting result was achieved several times, whereby gastroids
failed to form from mice that lacked Ifrd1 (Figure 5.1). While this was a promising result, it was
also surprising given our presumption that IFRD1 appears to function primarily on mature cells
undergoing paligenosis; thus, we would not expect the constitutively active stem cell to be
affected by Ifrd1 mutation.
Further work is needed to answer several question about IFRD1 and the formation of
organoids from gastric cells. The first experiment would be to find a consensus result from the
generation of gastric organoids from gastric units isolated from Ifrd1 null mice. Building on that
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study would be to isolate chief cells from gastric units of mice with and without Ifrd1 and
determine the efficiency of organoid generation in that context.
Gastroids provide a cell autonomous system in which to test molecular mechanisms of
paligenosis. Another system, for which I generated preliminary data, is the isolation and culture
of pancreatic acinar cell ex vivo. This system has the advantage of requiring only crude isolation
in order to enrich the cell population of interest (acinar cells), but a major disadvantage is that it
is difficult to propagate these cells for more than a few days. Isolated acinar cells will naturally
dedifferentiate and become more duct like in vitro (modeling acinar-ductal metaplasia in vivo),
but many cells die due to the abundance of digestive enzymes that are released during isolation5.
Developing this protocol further will enable large scale testing of paligenosis in a relatively
homogenous cell population, which is important for understanding the molecular changes that
occur during paligenosis.
There are numerous studies of interest in both gastric organoid and ex vivo acinar cell
culture models. Since rapamycin has such a strong effect in vivo, it would be important to test
the effects of rapamycin treatment on gastroid formation and dedifferentiation of isolated
pancreatic acinar cells. Along the same lines, both of these systems enable the investigation of
lysosome and autophagy dynamics. In relation to IFRD1, in vitro systems enable further analysis
of the interaction between IFRD1 and P53. Co-immunoprecipitation could be done robustly in
the cells of interest, as opposed to the mixed cell types in an in vivo tissue. Further, an epistatic
relationship could be determined through the administration of Nutlin-3, which is an MDM2
antagonist (resulting in the stabilization of P53). Lastly, in vitro assays would enable the direct
modulation of other major signaling pathways like JNK, HIPPO, MAPK and ribosomal stress
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(e.g. treat with the transcriptional inhibitor actinomycin D), all of which would increase
mechanistic evidence relating to IFRD1.

Single cell RNAseq in secretory cells undergoing paligenosis in the absence of Ifrd1
Rapid progress in the development of next-generation sequencing technologies in recent
years has provided insights into biological systems. Sequencing based technologies for
genomics, transcriptomics and epigenomics are now being focused on characterizing individual
cells. Traditional expression profiling that assesses bulk populations can create noise when
analyzing a process like paligenosis. Single cell RNAseq would be particularly useful in the
pancreas, a tissue which is primarily composed of acinar cells, but those cells are not
synchronized throughout injury. Characterizing the expression of pancreatic acinar cells (and
gastric chief cells) undergoing paligenosis at various timepoints would help dissect specific
expression profiles during the progression of paligenosis and potentially reveal regulatory
relationships between genes. This technology has routinely been used in mouse and human
pancreas, but not in the context of injury en route to metaplasia6-8.
IFRD1 Yeast 2 Hybrid
In November of 2017, we performed a Yeast 2 Hybrid screen to uncover which proteins
IFRD1 can interact with in vivo. This screen is a complementation assay that involves splitting a
transcription factor into two fragments (bound to two proteins of interest) and observing the
activation of a downstream reporter gene that is only transcribed when the two domains of the
transcription factor interact. Initial review of the data produced a few interactions of note,
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including: RPL19, RPL3, SMC6, ZNF574 and a screen of a short, but high identify match to
LAMTOR4 (Figure 5.2). Ribosomal proteins RPL19 and RPL3 are highly conserved and
involved in proliferation, ribosomogenesis, translation efficiency and management of nucleolar
stress in relation to p539-11. SMC6 is also highly conserved and manages DNA repair and
replication stress12. In yeast, in addition to DNA repair and homologous recombination, SMC6 is
essential for proliferation13. ZNF574 is one of seven genes that demonstrates highly differential
expression in early onset colorectal cancer compared to late onset colorectal cancer14. ZNF574 is
associated, like IFRD1, with the SIN3 complex, which, as described in Chapter 1, plays a role in
scaffolding histone deacetylases, histone and DNA methylation and the regulation of P53.
ZNF574 also interacts with NAT10, a nucleolar acetyltransferase that responds to stress by
promoting a transition from rRNA synthesis to autophagy. Lastly, LAMTOR4 (late
endosomal/lysosomal adapter and mitogen activated protein kinase and mechanistic target of
rapamycin activator 4) is one of five proteins that make up the Ragulator complex. This complex
is also conserved to yeast and its function it to anchor mTORC1 to the lysosomal membrane15. In
the absence of the Ragulator complex mTORC1 becomes constitutively inactivated in the
cytoplasm16.
None of the above described interactions can independently explain IFRD1 function, but
together they provide insight into how IFRD1 may function in the injury response and they are
each worthy of further exploration.
IFRD1 and Nucleolar Stress
I performed an analysis of cerulein treated Ifrd1 null vs WT mice in Partek that revealed
that several DEAD-box helicases were down-regulated in mice lacking Ifrd1 following 5 days of
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cerulein treatment. This analysis led us to begin investigating ways to interpret and analyze the
nucleolus in cells undergoing paligenosis. Immunoflourescent analysis of DDX21 revealed much
less expression in Ifrd1–/– mice treated with cerulein compared to wild type mice treated with
cerulein (Figure 5.3). Further, a relationship between IFRD1 and DDX21 was revealed through
Cord analysis which displays genes that have been shown to be co-regulated in experimental
contexts. I could not find a similar phenotype in the stomach so I have not continued to pursue
DDX21, but the nucleolus has remained an area of active investigation in the lab.
Nucleolar/ribosomal stress is one of the few pathways that we know are shared among cells
undergoing paligenosis and is conserved all the way to yeast. In the fly interactome (Drosophila
Interactions Database), we see that the Drosophila version of Ifrd1 interactions with
Nucleostemin 1 and 2. Nucleostemin is required for DDX21 localizing to the nucleolus and is
required for proliferating cells to pass through G1-phase17. A scenario where Ifrd1 is required to
scaffold Nucleostemin-DDX21 during stress, in order to maintain the suppression of p53 and
enable cell cycle progression, is worth investigation.
The nucleolus is also important because it functions to maintain a balance between
ribosomal RNAs (which are transcribed in the nucleolus) and ribosomal proteins is required to
prevent p53 stability and progress through the cell cycle18; Figure 1.5). We believe that the
apoptosis that we observe in stage 3 paligenotic cells of Ifrd1–/– mice is due to this stabilization
of p53. The nucleolus integrates a ton of information because it requires: transcription (Pol-I,
Pol-II and Pol-III), translation (of mTOR-dependent ribosomal proteins), nuclear import of
ribosomal proteins and assembly of the entire ribosome complex. Any imbalance leading to the
accumulation of ribosomal proteins that aren’t attached to ribosomal RNAs leads to MDM2
binding. The binding of MDM2 by ribosomal proteins liberates and, therefore, stabilizes p5319.
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Studies are underway in the lab to investigate morphological differences in the nucleoli
of wild type and Ifrd1–/– gastric and pancreatic cells undergoing paligenosis. Early indications
are that there is a difference in the number and size of nucleoli, however, more work is required
to identify specific nucleolar markers that can be analyzed in each context and link those
nucleolar markers to paligenosis-specific phenotypes.
IFRD1 and P53 transcription
We analyzed gene sets from microarrays performed following 5 days of cerulein
treatment in wild type and Ifrd1–/– mice. Given the stabilization of p53, we were interested in
identifying a molecular expression signature that would differentiate Ifrd1–/– from wild type mice
at the proliferation stage. Although we would expect all p53 target genes to be upregulated in
Ifrd1–/– mice (due to the stabilization of p53 protein), instead we observed that a subset of p53
target genes were actually downregulated in Ifrd1–/– mice at this time point. In Knights et al.,
they describe how p53 is regulated by stress-induced posttranslational modifications20. Specific
acetylated and phosphorylated residues of p53 influence gene expression patterns and,
ultimately, cell fate. They describe that there is a cassette of p53 genes that are related to growtharrest and another set which causes apoptosis. These gene sets can be delineated by their
expression in relation to p53 acetylation status. P300 acetylates lysines 370, 372, 373 and 382 in
the C-terminal portion of p5321. PCAF (p300-associated factor) has been linked to acetylation of
lysine 320, which is located within a flexible linker domain which also contains a nuclear
localization signal22,23. IFRD1 has been reported to form a complex with histone deacetylases,
thus, we would propose that IFRD1 could plug into the Sin3 complex to influence p53
acetylation status24. In the Genechip data, we observe a decrease in growth-arrest p53 targets,
like cdkn1 and sen2. This suggests that there is a relative loss of K320 P53 in the absence of
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IFRD1. If the loss of IFRD1 shifts the acetylation status of P53 from K320 to the K373 cassette,
it may explain why there is more apoptosis following injury. Further investigation would include
analyzing the difference between P53 gene cassettes and their relation to IFRD1. This would
help uncover the functional relationship between IFRD1 and P53 and the consequences on
paligenosis.
IFRD1 and Type I Interferons
A new angle on paligenosis is emerging in the lab, in relation to the role of Type I
Interferons and their effect on the injury observed in pancreas and stomach en route to
metaplasia. IFRD1 is highly conserved, and we speculated that it evolved as a way for cells to
differentiate between self and invading species that may try to take over host-protein translation
mechanisms. IFRD1 has been shown to be upregulated in human tissue following H. pylori
infection and Drosophila tissue following Pseudomonas infection. The literature has also shown
that IFRD1 can regulate viral immune evasion mechanisms in human papilloma virus-induced
keratinocytes25. Type I Interferon (type 1 IFN) genes are cytokines that play a role in the
induction of anti-viral gene program that is important for host defense against viruses. The type 1
interferon response, specifically genes associated with IFN-α and IFN-β, are upregulated in
Ifrd1–/– vs WT mice treated with cerulein. Further, IFN-α and IFN-β responsive genes are
upregulated in cerulein treated Ifrd1–/– vs. Rapamycin + Cerulein treated mice (Figure 5.4). This
Type I IFN response may account for the increased death that we observe in Ifrd1–/– mice treated
with long term cerulein compared to wild type mice.
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IFRD1 and Oxidative Phosphorylation
Metabolic reprogramming is a hallmark of tumor cell survival, proliferation and
resistance to therapy. Cancer cells exhibit a wide range of metabolic profiles but tend to favor
glycolysis over oxidative phosphorylation, even though glycolysis is much less efficient26. The
Warburg effect describes this preference and one of the reasons that it glycolysis may be
preferred in cancer cells is due impaired mitochondria, which function in apoptosis27.
Mitochondrial function is generally intact in most cancers, but in some cases mitochondrial
deficiencies can arise due to damage from the low-oxygen tumor environment or suppression by
cancer genes27. In tumors, p53 is often inactivated or deleted, yet paradoxically recent studies
have shown that activation of p53 impacts glucose metabolism and prevents more aggressive
cancer phenotypes28. P53 has been shown to revert the Warburg effect and negatively influence
the oncogenic metabolic adaptation of cancer cells29. A consistent molecular signature from the
analysis of cerulein gene chips from Ifrd1–/– vs. wild type mice reveals that genes associated with
the oxidative phosphorylation pathway are differentially expressed in Ifrd1–/– mice. As described
earlier, p53 is stabilized in Ifrd1–/– mice, and aberrant p53, even in non-tumor cells, may result in
a shift away from activation of genes associated with oxidative phosphorylation.
Previous work by the lab of Dr. Deborah Rubin has shown that overexpression of Ifrd1
causes metabolic changed in enterocytes30. They observed an increase in fatty acid absorption
and a decrease in the uptake of select amino acids in transgenic mice. Mice lacking Ifrd1 also
demonstrate metabolic deficiencies. For example, mice do not gain weight when chronically fed
a high-fat diet and tis7 deletion results in delayed lipid absorption and altered intestinal and
hepatic lipid trafficking31. This investigation establishes a link between IFRD1-induced lipid
metabolism, the inflammatory response to a high-fat diet, and survival after surgical resection32.
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IFRD1 and human cancer screening
As described earlier in Chapter 2, we find high IFRD1 expression is associated with
poorer patient survival in colorectal cancer. We proposed that IFRD1 regulates metabolic
processes in cancer cells, which may influence sensitivity to adjuvant chemotherapy. The precise
mechanism by which IFRD1 may work is unknown, but the IFRD1 exhibits promise in cancer
therapeutics as an indicator of high metabolic activity. We have shown, at the cellular level, that
IFRD1 marks cells that have recently sensed injury. In the absence of IFRD1, these cells still
sense damage, but they demonstrate a defect in the ability to resolve that injury. Our data show
that IFRD1 may function as a signal to the cell that entry into the cell cycle is safe. Aberrant or
hyperactivity of IFRD1 in tumors may suggest that these cells have the capacity to proliferate
while ignoring normal cellular checkpoints. I view the impact of IFRD1 in future therapies as
two-fold: 1) IFRD1 could serve as a marker on a genetic panel or screen that would highlight
tumors with high metabolic plasticity and 2) as a drug target, inhibiting IFRD1 function,
following the synchronization of tumor cells using chemotherapy. Since, IFRD1 seems
dispensable for normal homeostatic activity, its inhibition would specifically drive tumor cells
toward apoptosis.
Chapter 5.3 Conclusion
Paligenosis establishes a new field that begins to explain a phenomenon observed during
the injury response in numerous species and tissues. The characterization of IFRD1 in the
context of paligenosis will influence the investigation of numerous tissues and disease research.
The work described in this thesis details the launch of a new field of study and the first described
regulator of it.
183

Chapter 5.4 FIGURES

Figure 5.1

Figure 5.1 Preliminary gastric organoid data generated from wild type and Ifrd1 null mice.
Initial results showed increased death and poor organoid establishment in null mice, but further
experiments showed inconsistent results.
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Figure 5.2

Figure 5.2 Results from Yeast 2 Hybrid assay listing the potential proteins that can interact in
vitro.
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Figure 5.3

Figure 5.3 Preliminary results showing decreased DDX21 expression in Ifrd1 null mice treated
with cerulein compared to wild type mice.
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Figure 5.4

Figure 5.4 Comparison of interferon related gene expression after cerulein treatment in wt, Ifrd1
null and wt mice + rapamycin. The results show that all of the Interferon type 1-related genes are
upregulated in Ifrd1 nulls compared to wild type or rapamycin treated mice, which might
account for the increases apoptosis in Ifrd1 null mice treated with cerulein.
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